WO2011033633A1 - Lactase preparation - Google Patents

Lactase preparation Download PDF

Info

Publication number
WO2011033633A1
WO2011033633A1 PCT/JP2009/066231 JP2009066231W WO2011033633A1 WO 2011033633 A1 WO2011033633 A1 WO 2011033633A1 JP 2009066231 W JP2009066231 W JP 2009066231W WO 2011033633 A1 WO2011033633 A1 WO 2011033633A1
Authority
WO
WIPO (PCT)
Prior art keywords
lactase
arylsulfatase
gene
activity
preparation
Prior art date
Application number
PCT/JP2009/066231
Other languages
French (fr)
Japanese (ja)
Inventor
一磨 塩田
博文 堀口
愛 伊豫谷
吉川 潤
佐藤 智子
Original Assignee
合同酒精株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 合同酒精株式会社 filed Critical 合同酒精株式会社
Priority to PCT/JP2009/066231 priority Critical patent/WO2011033633A1/en
Publication of WO2011033633A1 publication Critical patent/WO2011033633A1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00Milk preparations; Milk powder or milk powder preparations
    • A23C9/12Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/1203Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
    • A23C9/1206Lactose hydrolysing enzymes, e.g. lactase, beta-galactosidase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14Fungi; Culture media therefor
    • C12N1/16Yeasts; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase

Definitions

  • the present invention relates to a lactase preparation in which arylsulfatase is not contaminated or very small even when contaminated, a method for producing such a lactase preparation, and a dairy product produced using such a lactase preparation.
  • milk Since ancient times, milk has long been used as a nutritious and useful food. Milk contains lactose, a kind of sugar. Lactose is broken down in the intestine by lactase, but in some humans, as the amount of lactase secreted into the intestine decreases as it grows, milk and milk processed products (hereinafter collectively referred to as “dairy products”) ) causes so-called lactose intolerance such as abdominal pain and diarrhea. This contributed to the widespread consumption of this nutritious food.
  • dairy products in which lactose has been reduced or removed in advance have been provided. Such a dairy product can be consumed without problems even by a human with lactose intolerance.
  • Lactose is reduced or removed by various methods, but the most common is a method of hydrolyzing lactose by treating a dairy product with a lactase preparation.
  • lactase preparation is aseptically added to sterilized milk and lactose is decomposed during distribution. This is believed to reduce the amount of lactase preparation used and contribute to cost reduction.
  • Patent Document 1 describes a lactase preparation in which the amount of arylsulfatase contamination is reduced and a method for producing the same.
  • arylsulfatase activity is not measured in a trace amount region of 8 units (arylsulfatase activity per 1 LLU of lactase active substance, the same shall apply hereinafter) or less, and is described as below the detection limit. It has only been done.
  • Table 1 of Patent Document 1 it is described that if the activity of contaminating arylsulfatase is 19 units or less, no odor is produced in the dairy product.
  • a general purification method such as adsorption, solvent fractionation, ammonium sulfate fractionation, chromatography, and crystallization may be combined.
  • a general purification method such as adsorption, solvent fractionation, ammonium sulfate fractionation, chromatography, and crystallization may be combined.
  • Arylsulfatase production ability is deleted.
  • a microorganism obtained by transforming a host that originally does not produce arylsulfatase to produce the target enzyme can also be used.
  • Patent Document 1 describes a method for obtaining a microorganism having reduced ability to produce arylsulfatase by mutation treatment and a microorganism having an arylsulfatase gene deleted by genetic engineering techniques.
  • a method for obtaining a microorganism in which arylsulfatase production ability has been reduced by mutation treatment has been described, there is no description of an actual acquisition example, and only the possibility has been shown. That is, it is unclear whether or not it is possible to produce a microorganism having an arylsulfatase production ability reduced by mutation treatment at an industrial level by the method described in Patent Document 1.
  • yeast diploid strains useful for industrial production of lactase formulations it is necessary to obtain double mutants to disrupt the arylsulfatase gene by mutation, and such double mutants Acquisition was considered difficult in practice.
  • Patent Document 1 only describes an example using a haploid strain called CBS2359 strain.
  • a haploid strain called CBS2359 strain it is difficult to effectively disrupt a gene in a diploid strain of yeast useful for the production of a lactase preparation. Therefore, aryl which is a diploid strain of yeast is used. A sulfatase non-producing strain cannot be produced.
  • the present inventors selected a highly sensitive fluorescence method as a method for measuring arylsulfatase activity, examined appropriate measurement conditions, and established a measurement method. And by the method for measuring the activity of arylsulfatase, arylsulfatase is used for measuring the activity of arylsulfatase in a region that has been conventionally below the detection limit, so as not to generate an unpleasant taste or smell in milk or dairy products. The amount of contamination was identified and the present invention was completed.
  • the present invention relates to a yeast diploid strain having a lactase gene and restricted expression of arylsulfatase protein, or a recombinant microorganism into which a yeast lactase gene has been introduced and expression of arylsulfatase protein is restricted.
  • the 4-methylumbelliferone concentration of the measurement sample is calculated, divided by 3, and the reaction time is 1 hour. If so, determine the 4-methylumbelliferone concentration. Further, the amount of 4-methylumbelliferone generated during the reaction for 1 hour is calculated from the volume of the reaction solution. (9) Since the amount of 4-methylumbelliferone calculated in this way is based on the amount of sample contained in the sample prepared in (1), it is converted to the amount of 4-methylumbelliferone per gram of sample. To do.
  • step (10) “substrate” is potassium 4-methylumbelliferone sulfate, and “enzyme” is arylsulfatase.
  • the arylsulfatase protein is not expressed, that is, the production amount is zero, but the arylsulfatase activity (unit: U / g) / lactase activity (unit: NLU / g) is 0.1% or less.
  • the expression of the arylsulfatase protein may be limited so as to be preferably 0.02% or less.
  • the lactase preparation according to the present invention preferably has a lactase activity of 1,000 NLU / g or more, more preferably 2,000 NLU / g or more, and further preferably 3,000 NLU / g or more. More preferably, it is more preferably 4,000 NLU / g or more, and most preferably 5,000 NLU / g or more.
  • the yeast diploid strain having a lactase gene and restricted expression of arylsulfatase protein may be a mutant strain obtained by a mutation treatment of a yeast diploid strain or a yeast diploid strain. It may be a mutant obtained by subjecting a body strain to deletion of an arylsulfatase gene or an arylsulfatase protein expression regulatory gene. A mutant strain whose parent strain is a diploid strain of yeast having a large production amount of lactase protein is preferred.
  • the diploid strain of yeast is preferably a diploid strain of Kluyveromyces lactis or its closely related species, Kluyveromyces marxianus.
  • the genetically modified microorganism into which the yeast lactase gene is introduced and the expression of the arylsulfatase protein is restricted is preferably a genetically modified microorganism into which the Klaveromyces lactis or Kriveromyces marixianus lactase gene is introduced.
  • the present invention relates to a yeast diploid strain having a lactase gene and restricted expression of an arylsulfatase protein, or a genetically modified microorganism into which a yeast lactase gene has been introduced and the expression of an arylsulfatase protein is restricted.
  • the present invention also relates to a method for producing a lactase preparation, which comprises culturing, recovering a culture solution with or without destroying cell walls, and preparing a lactase preparation. The case where the culture solution is collected without destroying the cell wall is a case where the genetically modified microorganism secretes lactase.
  • the preparation process of the lactase preparation may include purification steps performed in the art, such as concentration of lactase protein and removal of contaminants.
  • the produced lactase preparation has, for example, an arylsulfatase activity (unit: U / g) according to the activity measuring method according to the present invention described above / a lactase activity (unit: NLU / g) by the FCC IV method of 0.1%. It is as follows.
  • the present invention relates to a dairy product produced using the lactase preparation according to the present invention.
  • a conventionally known method for measuring the activity of arylsulfatase is a colorimetric method using a compound in which a sulfate group is bound to a chromophore such as p-nitrophenol as a substrate.
  • a chromophore such as p-nitrophenol
  • absorbance the amount of chromophore released by the removal of sulfate groups from the substrate due to the reaction between the substrate and arylsulfatase is measured by absorbance.
  • the amount of liberated chromophore such as p-nitrophenol is small, the change in absorbance is small and it is difficult to obtain a clear measured value.
  • a fluorescence method using a compound in which a sulfate group is bound to a fluorophore, such as 4-methylumbelliferyl sulfate, as a substrate is also known.
  • the sensitivity of the fluorescence method is generally said to be at least 100 times that of the colorimetric method. Therefore, the present inventors have examined the reaction conditions and measurement conditions between the substrate and the enzyme and established a highly sensitive measurement method for the fluorescence method for measuring arylsulfatase activity. By carrying out this highly sensitive activity measurement method, the amount of arylsulfatase contaminated in the lactase preparation can be accurately grasped. As a result, it has become possible to provide lactase preparations having zero or very little arylsulfatase content.
  • the method for measuring the activity of arylsulfatase according to the present invention is as follows.
  • a specimen in which the presence of arylsulfatase is predicted is appropriately diluted with a 100 mM potassium phosphate buffer (pH 6.5) containing 0.5 N potassium chloride to prepare a sample.
  • An aqueous solution containing 2-methylumbelliferone sulfate potassium at a concentration of 2 mM is prepared.
  • the sample and a 4-methylumbelliferone sulfate aqueous solution are mixed at 1: 1 (volume basis) and reacted at 37 ° C. for 3 hours.
  • To the reaction solution add the same amount (volume basis) of 0.1N sodium hydroxide aqueous solution as the reaction solution to stop the reaction and prepare a measurement sample.
  • the fluorescence intensity is measured at an excitation wavelength of 360 nm and a fluorescence wavelength of 450 nm.
  • (6) 4-Methylumbelliferone is dissolved in a 100 mM potassium phosphate buffer (pH 6.5) containing 0.5N potassium chloride to obtain a solution with an appropriate concentration. An aqueous sodium oxide solution is added, and the fluorescence intensity is measured under the same conditions as in (5).
  • a calibration curve is created from (6).
  • the 4-methylumbelliferone concentration of the measurement sample is calculated, divided by 3, and the reaction time is 1 hour. If so, determine the 4-methylumbelliferone concentration.
  • the amount of 4-methylumbelliferone generated during the reaction for 1 hour is calculated from the volume of the reaction solution. (9) Since the amount of 4-methylumbelliferone calculated in this way is based on the amount of sample contained in the sample prepared in (1), it is converted to the amount of 4-methylumbelliferone per gram of sample. To do. (10) The case where the amount of 4-methylumbelliferone produced per 1 hour of the reaction time between the substrate and the enzyme is 1 nmole is defined as 1 unit (U), and the unit is the unit amount per 1 g of the specimen, that is, the enzyme preparation, That is, it is represented by “unit (U) / g”.
  • lactase preparation according to the present invention was measured by the above method, and the calculated arylsulfatase activity was determined by the FCC IV method (Food Chemicals Codex Fourth Edition, Effective Jury 1, 1996, Committee on Food 2 Chemical 80. Chemp. 80 ) Based on lactase activity (unit: NLU / g), it is 0.1% or less, preferably 0.02% or less.
  • a diploid strain of yeast that produces lactase protein has a lactase gene, and is restricted in the expression of arylsulfatase protein is used.
  • a yeast diploid strain is, for example, a mutant strain obtained by microbial mutation treatment.
  • mutant strains can be treated by exposing yeast to UV irradiation or chemical mutagens to destroy the arylsulfatase gene or the arylsulfatase protein expression regulatory gene for both diploid genes.
  • a deletion method a method of deleting an arylsulfatase gene or an expression regulator gene of an arylsulfatase protein by genetic engineering techniques, etc. for both diploid genes.
  • Whether or not a desired mutant strain has been obtained may be determined by measuring the arylsulfatase activity of the cultivated yeast culture solution by the method for measuring arylsulfatase activity (fluorescence method) according to the present invention.
  • Induction of mutation by ultraviolet rays is performed, for example, by irradiating a suspension of diploid yeast with ultraviolet rays.
  • chemical mutagenesis is performed by adding a chemical mutagen to a suspension of diploid yeast, for example.
  • chemical mutagens include 5-bromouracil, 2-aminopurine, nitrous acid, hydroxylamine, acriflavine, methanesulfonic acid compound, nitrosoguanidine and the like.
  • a gene fragment having a homologous sequence of the gene to be deleted is obtained, and the fragment is subcloned into a vector and deleted.
  • Ordinary genetic engineering techniques such as constructing a disruption vector for a power gene and transforming a diploid strain of yeast using the vector, may be applied.
  • a recombinant microorganism into which a yeast lactase gene is introduced so as to express a lactase protein and the expression of an arylsulfatase protein is restricted can also be used.
  • arylsulfatase protein is restricted
  • a gene involved in the production of arylsulfatase protein is restricted, and more specifically, arylsulfatase gene and / or Because there is no aryl sulfatase protein expression regulatory gene, or because the aryl sulfatase gene (structural gene) is disrupted or the expression regulatory gene that causes the aryl sulfatase gene to express the aryl sulfatase protein is disrupted It means that arylsulfatase protein is not produced or its production amount is reduced.
  • a genetically modified microorganism into which a yeast lactase gene is introduced and the expression of arylsulfatase protein is restricted can be prepared by a known method.
  • a lactase gene is incorporated into a plasmid resistant to drug A and, if necessary, an expression control gene for the lactase gene is incorporated at the same time.
  • the lactase expression plasmid thus prepared is used to transform a host microorganism.
  • the transformed microorganism is cultured in a medium containing the drug A, and the appearing colonies are selected.
  • E. coli, yeast, Bacillus subtilis, etc. can be used as a host for obtaining a genetically modified microorganism into which a yeast lactase gene has been introduced and the expression of arylsulfatase protein is restricted.
  • a host for obtaining a recombinant microorganism into which a yeast lactase gene has been introduced and the expression of arylsulfatase protein is restricted a host that does not have an arylsulfatase gene or an arylsulfatase protein expression regulatory gene, or an arylsulfatase A host in which a gene or an arylsulfatase protein expression regulatory gene is disrupted or deleted is desirable.
  • a lactase for a lactase preparation is a yeast diploid strain that has a lactase gene and the expression of an arylsulfatase protein is restricted, or a gene set in which a yeast lactase gene is introduced and the expression of an arylsulfatase protein is restricted Purify from the culture solution of the replacement microorganism. Note that the concept of “culture solution” includes a culture supernatant and an extract from recovered cells.
  • Incubation of microorganisms such as yeast can be performed using an incubator such as a flask, miniger, tank, etc.
  • an incubator such as a flask, miniger, tank, etc.
  • As culture conditions a temperature, pH, number of stirring, etc. suitable for enzyme production by the microorganisms are selected.
  • a culture solution in which lactase is dissolved is usually obtained by breaking the cell wall.
  • the microorganisms used for culture secrete lactase the cell wall need not be destroyed.
  • the culture solution is usually separated into a culture supernatant and a residue by an appropriate method usually used in this technical field, such as centrifugation, filtration, or the like.
  • the culture supernatant may be used as it is as an enzyme solution, or may be used as an enzyme solution after being concentrated using an ultrafiltration membrane or the like.
  • a culture solution or culture supernatant that has been purified by subjecting it to one or more purification operations such as adsorption, solvent fractionation, ammonium sulfate fractionation, chromatography, crystallization, etc. may be used as an enzyme solution.
  • the enzyme solution may be pulverized by a method such as spray drying or freeze drying.
  • the enzyme solution itself thus obtained can also be used as a lactase preparation.
  • the essential component of the lactase preparation according to the present invention is lactase.
  • the lactase preparation contains other components as long as it is a substance that does not inhibit the activity of the lactase and does not inhibit the activity, or unless it has an undesirable effect on the intended use of the lactase preparation. May be present.
  • substances that may be present include starches, dextrin, and buffering agents that are excipients for ease of use, such as metal salts that contribute to the stabilization of lactase, various sugars, ascorbic acid, glycerin, etc. Inorganic salts and the like.
  • the properties of the lactase preparation are not particularly limited, and may be, for example, powder, granules, solutions and the like.
  • the present invention also relates to a dairy product produced using the lactase preparation according to the present invention.
  • Dairy products refer to milk such as long life milk, yogurt, fresh cream, sour cream, cheese and the like.
  • the lactase preparation is used in a usual manner or use amount in this technical field.
  • Example 1 Measurement of arylsulfatase activity by a conventionally known colorimetric method GODO-YNL2 (Lactase preparation manufactured by Godo Shusei Co., Ltd.) is dissolved in distilled water to obtain a 1% (w / v) solution. It was. This 1% solution was diluted with 100 mM potassium phosphate buffer (pH 6.5) containing 0.5 N potassium chloride, 0.8% (w / v), 0.6% (w / v), 0.4% (w / v) and 0.2% (w / v) solutions were obtained.
  • Example 2 Measurement of Aryl Sulfatase Activity by Fluorescence Method
  • GODO-YNL2 (Lactase preparation manufactured by Godo Sakesei Co., Ltd.) was dissolved in 100 mM potassium phosphate buffer (pH 6.5) containing 0.5 N potassium chloride. % (W / v) solution was obtained. This 1% solution was diluted with the same buffer and 0.8% (w / v), 0.6% (w / v), 0.4% (w / v) and 0.2% ( w / v) A solution was obtained.
  • Example 3 Comparison between colorimetric method and fluorescence method in measuring arylsulfatase activity The difference in sensitivity between the colorimetric method and fluorescence method in measuring arylsulfatase activity was examined. First, purified lactase used in this experiment was prepared.
  • the plate was washed with 40 L of 10 mM potassium phosphate buffer (pH 7) containing 50 mM sodium chloride, and then lactase was eluted with 200 L of 10 mM potassium phosphate buffer (pH 7) containing 100 mM sodium chloride. At this time, the fraction was fractionated into 20 L portions.
  • Lactase activity of each fraction (according to FCC IV method; Food Chemicals Codex Fourth Edition, Effective July 1, 1996, Committee on Food Chemicals p.801-802) and aryl sulfatase activity as described in detail below; ) was collected, and the fraction in which arylsulfatase was reduced was collected, mixed, and concentrated using an ultrafiltration membrane (ACP membrane manufactured by Asahi Kasei Corporation) to obtain a lactase concentrate. Glycerin was added to this concentrated solution to 50% (w / w) to obtain a purified lactase preparation.
  • ACP membrane manufactured by Asahi Kasei Corporation ACP membrane manufactured by Asahi Kasei Corporation
  • the purified lactase preparation prepared as described above and GODO-YNL2 are appropriately mixed to prepare lactase preparations with various arylsulfatase contamination rates, and lactase activity (by FCC IV method) and arylsulfatase activity (colorimetric method) And by fluorescence method).
  • an aqueous solution containing p-nitrophenol at a concentration of 0 to 0.5 mM was prepared.
  • 0.5 mL of a 100 mM potassium phosphate buffer solution (pH 6.5) was added to 0.5 mL of each of these solutions, and 1.5 mL of a 1.5N sodium hydroxide aqueous solution was further added to obtain a measurement sample.
  • Absorbance at 410 nm was measured to prepare a calibration curve.
  • the lactase preparation was diluted with a 100 mM potassium phosphate buffer (pH 6.5) containing 0.5N potassium chloride to obtain a 1% (w / v) solution.
  • a 100 mM potassium phosphate buffer (pH 6.5) containing 0.5N potassium chloride was obtained.
  • 0.5 mL of 2 mM 4-methylumbelliferyl sulfate aqueous solution was added to 0.5 mL of this 1% solution and reacted at 37 ° C. for 3 hours.
  • the reaction was stopped by adding 1 mL of a 0.1N sodium hydroxide aqueous solution, and the fluorescence intensity was measured at an excitation wavelength of 360 nm and a fluorescence wavelength of 450 nm.
  • a 100 mM potassium phosphate buffer (pH 6.5) containing 0.5N potassium chloride containing 4-methylumbelliferone at a concentration of 0 to 4 ⁇ M was prepared.
  • a sample for measurement was obtained by adding 1 mL of a 0.1 N aqueous sodium hydroxide solution to 1.0 mL of each of these solutions.
  • the fluorescence intensity was measured at an excitation wavelength of 360 nm and a fluorescence wavelength of 450 nm to prepare a calibration curve.
  • WO07 / 060247 states that a lactase preparation having 19 or less contaminating arylsulfatases (units defined in WO07 / 060247) does not produce off-flavors when added to decompose lactose after sterilization of milk.
  • WO07 / 060247 states that a lactase preparation having 19 or less contaminating arylsulfatases (units defined in WO07 / 060247) does not produce off-flavors when added to decompose lactose after sterilization of milk.
  • this is a view based on the results of a test conducted by limiting the reaction days of lactase to 2 days.
  • lactase preparations containing arylsulfatase at various contamination rates were prepared, added to milk, and the flavor was confirmed after a predetermined number of days.
  • Lactase preparations A to E containing various contaminating amounts of arylsulfatase include the purified lactase preparation prepared in Example 3 and GODO-YNL2 containing 100 units of the selected arylsulfatase activity (units described in WO07 / 060247). Were mixed as appropriate.
  • the arylsulfatase activities of the prepared lactase preparations A to E were measured by the method described in WO07 / 060247 and the fluorescence method shown in Example 3. Moreover, the lactase activity was measured by FCC IV method. The results are shown in Table 2.
  • the unit described in WO07 / 060247 is ⁇ OD 410 ⁇ 10 6 / hour / NLU.
  • each of lactase preparations A to E was added to commercially available milk (heat pasteurized; pasteurized conditions: 130 ° C. for 2 seconds) so that lactase was 20000 NLU / L-milk. And stored at 30 ° C. After 2 days of storage, after 1 month, and after 3 months, a flavor sensory test was conducted on milk not added with lactase preparation and milk added with lactase preparation.
  • the flavor sensory test was conducted as a blind test. Eleven to thirteen panelists sniffed the milk after storage for a certain period of time, and also judged whether it had a smell that was uncomfortable and contained in the mouth. The evaluation was made with a score of 0 (-) for those that did not feel odor, 1 (+) for those that felt odor, and 2 (++) for those that felt strong. The summarized results are shown in Table 3.
  • lactase preparation A or B that is, those having arylsulfatase activity by the method of the present invention / actase activity by the FCC IV method of 0.02% or less
  • lactase preparation A it became clear that the use of was more preferable.
  • the arylsulfatase activity value comparable to lactase preparations A and B needs to be measured by the fluorescence analysis method described in this specification or an analysis method showing sensitivity equal to or higher than that. .
  • Example 5 Acquisition of mutant strain with reduced arylsulfatase production ability Cliveromyces lactis G14-427 strain, a diploid strain, was added to 10 mL of YPD medium (1% yeast extract, 1% glucose, 2% peptone). 1 platinum ear was inoculated, and this bacterial suspension was stored at 30 ° C. and cultured. When the logarithmic growth phase was reached, the medium was centrifuged to recover the bacterial cells. The collected cells were dispersed in sterilized water so that the absorbance at 600 nm was 0.5. The bacterial suspension was irradiated with ultraviolet rays for 15 seconds with a UV lamp.
  • YPD medium 1% yeast extract, 1% glucose, 2% peptone
  • the cells were collected by centrifugation and mixed and dispersed in the YPD medium. An appropriate amount was taken from the YPD medium containing the bacterial cells and applied to the YPD agar plate medium. Static culture was performed at 37 ° C. for 7 days. A small amount of the grown colonies were scraped, and this was mixed with 1 mL of a solution containing zymolyce (manufactured by Seikagaku Biobusiness Co., Ltd.) at 1 mg / mL. The reaction was carried out at 30 ° C. for 2 hours to destroy the cell wall. Thereafter, centrifugation was performed and the supernatant was collected.
  • zymolyce manufactured by Seikagaku Biobusiness Co., Ltd.
  • the lactase activity (FCC IV method) and arylsulfatase activity (by the fluorescence method described in Example 3) of the supernatant were measured.
  • the arylsulfatase activity / lactase activity was calculated, and the one with a small value was selected.
  • mutant strain (SM1182 strain) was subjected to mutation treatment as a parent strain, and the other arylsulfatase gene also became dysfunctional, that is, a mutant strain having an arylsulfatase activity of 0 was obtained (SF-81 strain) ).
  • the parent strain Kriveromyces lactis G14-427 and two mutant strains obtained as described above were each cultured with shaking in a YPD medium (70 mL / flask) at 26 ° C. for 4 days.
  • Example 6 Acquisition of host strain The diploid strain Kriveromyces lactis G14-427 was inoculated with 1 platinum ear in 10 mL of YPD medium and grown at 30 ° C until the logarithmic growth phase. The medium was centrifuged and the cells were collected. The collected cells were dispersed in sterilized water so that the absorbance at 600 nm was 0.5. The bacterial suspension was irradiated with ultraviolet rays for 15 seconds with a UV lamp. The cells were collected by centrifugation and mixed and dispersed in the YPD medium. An appropriate amount was taken from the YPD medium containing the bacterial cells and applied to the YPD agar plate medium. Static culture was performed at 37 ° C. for 4 days. The grown colonies were replicated in SD medium (east nitrogen base containing no 0.67% amino acid, 2% glucose, 2% agar), and those that did not grow were selected.
  • SD medium east nitrogen base containing no 0.67% amino acid, 2% glucose, 2% agar
  • Table 5 shows the growth of the acquired auxotrophic mutants.
  • Example 7 Acquisition of gene double disruption strain that does not produce arylsulfatase (acquisition of host strain)
  • 8-23 strain which is the L-histidine and L-methionine double auxotrophic mutant strain obtained in Example 6, the respective auxotrophy is complemented by the HIS4 gene and the MET6 gene introduced by the lithium acetate method. I was sure that.
  • Genomic DNA was prepared from the obtained culture solution using Gen Torukun TM (for yeast) (Takara Bio Inc.). The operation was performed according to the description of Gen Torukun TM (for yeast).
  • PCR was performed using the above primers under the following conditions to obtain a DNA fragment.
  • Takara Ex Taq registered trademark; manufactured by Takara Bio Inc.
  • the polymerase was used as the polymerase, and the operation was performed according to the attached document.
  • the obtained fragment was purified by MagExtractor TM -PCR & Gel Clean up- (manufactured by Toyobo Co., Ltd.), and then ligated with a pGEM (registered trademark) -T vector (manufactured by Promega).
  • pGEM registered trademark
  • -T vector manufactured by Promega
  • DNA Ligation Kit ⁇ Mighty Mix> manufactured by Takara Bio Inc.
  • Usage was in accordance with each package insert.
  • E. coli prepared by the Hanahan method (Hanahan, D., J. Mol. Biol., 166, 557 (1983)).
  • a competent cell of ColiDH5 ⁇ strain was transformed, and a plasmid was extracted from the obtained transformant culture solution using MagExtractor TM -Plasmid- (manufactured by Toyobo Co., Ltd.). Usage followed the package insert. As a result, a plasmid pGSuC in which the target fragment was subcloned was obtained.
  • PCR was performed using primers BGLHIS4-F and HIS4-R using genomic DNA as a template to obtain a fragment containing the HIS4 gene.
  • the method described above was followed.
  • the obtained fragment containing the HIS4 gene was treated with Bgl II and EcoRI and inserted into the Bgl II-EcoRI site of pGSuC.
  • the plasmid constructed in this way was named pdSuC1.
  • Various methods at the time of construction were the same as those described above.
  • primers SuCd-M6F and SuCd-M6R were designed by adding 40 bases of the homologous sequence of the arylsulfatase gene to the 5 ′ side.
  • the homologous sequence of the arylsulfatase gene was in the vicinity of the restriction enzyme ClaI site present in two places on the open reading frame.
  • a fragment having an arylsulfatase homologous sequence at both ends of the MET6 gene was obtained using genomic DNA as a template.
  • the obtained fragment was subcloned into pGEM (registered trademark) -T vector (Promega) to obtain pdSuCM6.
  • pGEM registered trademark
  • -T vector Promega
  • FIG. 5 shows a schematic diagram of the construction of the transformant.
  • the plasmid pdSuC1 is linearized by treatment with NcoI and AatII, and the strain 8-23 is transformed by the lithium acetate method using this, and the transformant SuCD grows in SD medium supplemented with 20 ⁇ g / ml methionine. Acquired shares.
  • the plasmid pdSuCM6 was treated with ClaI to form a linear form, and the SuCD strain was transformed by the lithium acetate method using it to obtain a transformant SuCDD5-2 strain that grew on the SD medium.
  • genomic DNA was prepared from the culture solution using Gentorikun TM (for yeast) (manufactured by Takara Bio Inc.).
  • Gentorikun TM for yeast
  • the obtained genomic DNA was digested with BamHI and then subjected to Southern analysis.
  • the probe used was an AatII-EcoRI fragment of an arylsulfatase gene, and for labeling and detection of nucleic acids, AlkPhos Direct Labeling and Detection System with CDP-Star (manufactured by GE Healthcare Biosciences) was used. I followed.
  • Lane 1 is the parent strain G14-427
  • Lane 2 is the transformant SuCDD5-2 strain
  • Lane 3 is the transformant SuCD strain.
  • lane 3 a band (12.1 kb) of the fragment containing the arylsulfatase gene and the HIS4 gene was detected at the same position (7.8 kb) as in lane 1, and only one of the arylsulfatase genes was destroyed. It was confirmed that On the other hand, in lane 2, the 7.8 kb band was shifted to 5.3 kb, confirming that it was an arylsulfatase gene double disruption strain.
  • the culture medium of the SuCDD5-2 strain contains lactase, but does not contain arylsulfatase, or even if it is contained, the amount of the activity may not be detected by fluorescence measurement. It became clear. That is, it was confirmed that the SuCDD5-2 strain maintained lactase productivity but had no or almost no arylsulfatase productivity.
  • Example 8 Preparation of enzyme preparation
  • the strain SF-81 obtained in Example 5 was inoculated into a lactase production medium containing 7% corn steep liquor and 2% lactose, and the mixture was incubated at 30 ° C and 210 rpm for 96 hours. After shaking culture, the cells were collected by centrifugation. Sterile purified water was added to the cells, the cell walls of the collected cells were broken with glass beads and ultrasonic waves, and the supernatant was collected by centrifugation. The supernatant was fractionated with ammonium sulfate and concentrated with an ultrafiltration membrane to obtain a lactase preparation having a lactase activity of 5000 NLU / g. The arylsulfatase activity of this lactase preparation was 1 U / g or less according to the measurement method (fluorescence method) of the present invention.
  • Example 9 Sensory sensory test (2) (Preparation of lactase preparations with various arylsulfatase contamination rates)
  • a lactase preparation itself produced from the SF-81 strain by the method described in Example 8 and an appropriate mixture of GODO-YNL2 and an arylsulfatase activity measured by the fluorescence method described in Example 3 are 1 to 20 U / 5 lactase preparations were prepared.
  • the lactase activity of each lactase preparation was measured by FCC IV method.
  • Example 4 As in Example 4, each of the above 5 lactase preparations was added to commercially available milk so that the lactase was 20000 NLU / L-milk and stored at 30 ° C. After 1 month of storage, a flavor sensory test was performed in the same manner as in Example 4 to compare milk without a lactase preparation and milk with a lactase preparation. The results are shown in Table 8.
  • the arylsulfatase activity measured by the method according to the present invention is preferably 5 U / g or less.
  • the ratio of arylsulfatase activity (unit: U / g) measured by the method according to the present invention based on lactase activity (unit: NLU / g) by FCC IV method may be 0.1% or less. It became clear that it was preferable.

Abstract

Contaminating arylsulfatase in a lactase preparation causes the generation of unpleasant and offensive taste and odor in a food such as a milk product to which the lactase preparation is added. To overcome this problem, it is required to establish a method for measuring arylsulfatase at a high sensitivity. It is also required therefor to develop a lactase preparation in which the content of contaminating arylsulfatase is minimized or, preferably, a lactase preparation from which arylsulfatase is completely removed. A lactase preparation, which is produced by using, as a starting material, a liquid culture medium of a diploid yeast strain carrying lactase gene and showing regulated expression of arylsulfatase protein, or a genetically-modified microorganism carrying lactase gene of a yeast having been transferred thereinto and showing regulated expression of arylsulfatase protein, which shows an arylsulfatase activity of 0.1% or lower on the basis of the lactase activity when measured by a fluorescence method.

Description

ラクターゼ製剤Lactase preparation
 本発明は、アリールスルファターゼが夾雑しないか又は夾雑してもごく微量であるラクターゼ製剤、そのようなラクターゼ製剤の製造方法、及びそのようなラクターゼ製剤を用いて製造された乳製品に関する。 The present invention relates to a lactase preparation in which arylsulfatase is not contaminated or very small even when contaminated, a method for producing such a lactase preparation, and a dairy product produced using such a lactase preparation.
 古来より、牛乳は栄養豊かな有用食品として長く利用されてきた。牛乳には、糖の一種である乳糖が含まれている。乳糖はラクターゼによって腸内で分解されるが、ヒトの一部においては、成長するに従ってラクターゼの腸内への分泌量が減少するため、牛乳や乳加工製品(以下、まとめて「乳製品」という)を多量に摂取したときに、腹痛や下痢などのいわゆる乳糖不耐症を引き起こす。このことが、この栄養豊かな食品の幅広い摂取を妨げる一因となっていた。 Since ancient times, milk has long been used as a nutritious and useful food. Milk contains lactose, a kind of sugar. Lactose is broken down in the intestine by lactase, but in some humans, as the amount of lactase secreted into the intestine decreases as it grows, milk and milk processed products (hereinafter collectively referred to as “dairy products”) ) Causes so-called lactose intolerance such as abdominal pain and diarrhea. This contributed to the widespread consumption of this nutritious food.
 近年になり、乳糖が前もって低減あるいは除去された乳製品が提供されるようになってきた。このような乳製品であれば、乳糖不耐症のヒトでも問題なく摂取できる。 In recent years, dairy products in which lactose has been reduced or removed in advance have been provided. Such a dairy product can be consumed without problems even by a human with lactose intolerance.
 乳糖の低減あるいは除去は種々の方法で実施されているが、最も一般的なのは、乳製品をラクターゼ製剤で処理して乳糖を加水分解する方法である。 Lactose is reduced or removed by various methods, but the most common is a method of hydrolyzing lactose by treating a dairy product with a lactase preparation.
 ところで、これまでは、ラクターゼによって乳糖が分解された乳製品は、殺菌工程を経て流通されることが一般的であった。しかし、最近になり、殺菌後の牛乳に無菌的にラクターゼ製剤を添加し、流通中に乳糖を分解する手法が広まってきている。これは使用するラクターゼ製剤の量を減少せしめ、コスト減少に寄与すると考えられている。 By the way, until now, dairy products in which lactose has been decomposed by lactase have been generally distributed through a sterilization process. However, recently, a method has been widely used in which lactase preparation is aseptically added to sterilized milk and lactose is decomposed during distribution. This is believed to reduce the amount of lactase preparation used and contribute to cost reduction.
 一方、殺菌後の牛乳に無菌的にラクターゼ製剤を添加する方法の採用により、新たな問題が生じてきた。それは、ラクターゼ製剤中に微量に含まれる夾雑酵素(プロテアーゼやアリールスルファターゼ)が失活していないため、乳成分に化学変化をもたらすことに起因する問題である。実際、プロテアーゼが凝乳や苦味の発生を引き起こすことが知られており、また、非特許文献1には、アリールスルファターゼが違和感のある好ましくない味と臭いの発生を引き起こすことが報告されている。 On the other hand, new problems have arisen by adopting a method of aseptically adding a lactase preparation to sterilized milk. It is a problem caused by causing chemical changes in milk components because contaminant enzymes (proteases and arylsulfatases) contained in trace amounts in lactase preparations are not inactivated. In fact, it is known that proteases cause curdling and bitterness, and Non-Patent Document 1 reports that arylsulfatase causes unpleasant taste and odor.
 特許文献1には、アリールスルファターゼの夾雑量を減少させたラクターゼ製剤とその製造方法が記載されている。しかしながら、特許文献1に記載のアリールスルファターゼ活性の測定方法では、8単位(ラクターゼ活性体1NLU当たりのアリールスルファターゼ活性、以下同様)以下の微量領域ではアリールスルファターゼ活性が測定されず、検出限界以下と記載されているのみである。また、特許文献1の表1には、夾雑するアリールスルファターゼの活性が19単位以下であれば、乳製品に異臭を生じさせないと記載されている。しかし、これは、反応日数が2日間という短期間の試験における結果に基づく判断である。乳製品における異臭の発生原因が、アリールスルファターゼという酵素による乳成分の化学変化であることから推察すると、用途としてロングライフミルクを想定した場合、最大2~3ヶ月間の反応期間が想定される。そうであれば、特許文献1に記載の方法で測定したアリールスルファターゼ活性が19単位以下であれば乳製品に異臭を生じさせない、とはいえない。アリールスルファターゼの夾雑量に関し、さらに厳密なコントロールが必要であることは、また、アリールスルファターゼの夾雑量をコントロールするために、より精度の高いアリールスルファターゼ活性測定方法の採用が必要であることは、言を待たない。 Patent Document 1 describes a lactase preparation in which the amount of arylsulfatase contamination is reduced and a method for producing the same. However, in the method for measuring arylsulfatase activity described in Patent Document 1, arylsulfatase activity is not measured in a trace amount region of 8 units (arylsulfatase activity per 1 LLU of lactase active substance, the same shall apply hereinafter) or less, and is described as below the detection limit. It has only been done. In Table 1 of Patent Document 1, it is described that if the activity of contaminating arylsulfatase is 19 units or less, no odor is produced in the dairy product. However, this is a judgment based on the results of a short-term test with a reaction period of 2 days. Presuming that the cause of the off-flavor in dairy products is a chemical change in the milk component by the enzyme arylsulfatase, a reaction period of up to 2 to 3 months is assumed when long-life milk is assumed as the application. If so, it cannot be said that if the arylsulfatase activity measured by the method described in Patent Document 1 is 19 units or less, no off-flavor is produced in the dairy product. The fact that more precise control is required regarding the amount of arylsulfatase contamination also means that more accurate methods for measuring arylsulfatase activity are required to control the amount of arylsulfatase contamination. Don't wait.
 酵素製剤に夾雑するアリールスルファターゼを極限まで除去するには、一般的な精製方法である吸着、溶剤分画、硫安分画、クロマトグラフィー、結晶化などの方法を組み合わせて実施すればよい。あるいは、目的の酵素を生産する微生物であって、アリールスルファターゼ生産能を欠失したものを選別、育種すればよい。また、もともとアリールスルファターゼを産生しない宿主を、目的酵素を生産するように形質転換した微生物を使用することもできる。 In order to remove the arylsulfatase contaminating the enzyme preparation to the utmost limit, a general purification method such as adsorption, solvent fractionation, ammonium sulfate fractionation, chromatography, and crystallization may be combined. Or what is necessary is just to select and breed the microorganisms which produce the target enzyme, Comprising: Arylsulfatase production ability is deleted. In addition, a microorganism obtained by transforming a host that originally does not produce arylsulfatase to produce the target enzyme can also be used.
 特許文献1には、変異処理によるアリールスルファターゼ生産能を減じた微生物の取得方法と、遺伝子工学的手法によってアリールスルファターゼ遺伝子を欠失させた微生物に関する記載がある。ただし、変異処理によってアリールスルファターゼ生産能を減じた微生物の取得方法について、記載はされているが、実際の取得例の記載はなく、その可能性が示されているだけである。即ち、特許文献1に記載の方法により、変異処理によってアリールスルファターゼ生産能を減じた微生物の工業レベルでの生産が可能であるか否かは不明である。ラクターゼ製剤の工業レベルでの生産に有用な酵母の二倍体菌株において、突然変異によってアリールスルファターゼ遺伝子を破壊するには二重変異体を得ることが必要であり、そのような二重変異体の取得は、実際には困難であると考えられた。 Patent Document 1 describes a method for obtaining a microorganism having reduced ability to produce arylsulfatase by mutation treatment and a microorganism having an arylsulfatase gene deleted by genetic engineering techniques. However, although a method for obtaining a microorganism in which arylsulfatase production ability has been reduced by mutation treatment has been described, there is no description of an actual acquisition example, and only the possibility has been shown. That is, it is unclear whether or not it is possible to produce a microorganism having an arylsulfatase production ability reduced by mutation treatment at an industrial level by the method described in Patent Document 1. In yeast diploid strains useful for industrial production of lactase formulations, it is necessary to obtain double mutants to disrupt the arylsulfatase gene by mutation, and such double mutants Acquisition was considered difficult in practice.
 また、遺伝子工学的手法によるアリールスルファターゼ遺伝子の欠失については、特許文献1には、CBS2359株という一倍体菌株での実施例が記載されているのみである。換言すると、特許文献1に記載の方法では、ラクターゼ製剤の製造に有用な酵母の二倍体菌株において遺伝子を効果的に破壊することが困難であり、従って、酵母の二倍体菌株であるアリールスルファターゼ非生産株を作製することはできない。 Further, regarding deletion of the arylsulfatase gene by genetic engineering techniques, Patent Document 1 only describes an example using a haploid strain called CBS2359 strain. In other words, in the method described in Patent Document 1, it is difficult to effectively disrupt a gene in a diploid strain of yeast useful for the production of a lactase preparation. Therefore, aryl which is a diploid strain of yeast is used. A sulfatase non-producing strain cannot be produced.
特表2009-517061Special table 2009-517061
 ラクターゼ製剤中のアリールスルファターゼ夾雑量が微量であっても、そのラクターゼ製剤を乳あるいは乳製品に添加して使用した際に、その作用時間や温度条件などによって、違和感のある好ましくない味と臭いが発生され得る。そのような不都合を生じないためには、アリールスルファターゼの夾雑量が極限まで低減された、好ましくはアリールスルファターゼが完全に除去されたラクターゼ製剤を製造することが必要である。 Even if the amount of arylsulfatase contamination in the lactase preparation is very small, when the lactase preparation is added to milk or dairy products, it may have an unpleasant taste and smell that is uncomfortable depending on the action time and temperature conditions. Can be generated. In order not to cause such inconvenience, it is necessary to produce a lactase preparation in which the amount of contamination of arylsulfatase is extremely reduced, and preferably arylsulfatase is completely removed.
 本発明者等は、上記課題を解決するに先立ち、アリールスルファターゼ活性の測定方法として感度の高い蛍光法を選択し、適切な測定条件を検討し、測定方法を確立した。そして、そのようなアリールスルファターゼ活性の測定方法によって、従来は検出限度以下とされていた領域において、アリールスルファターゼの活性を測定し、乳や乳製品に好ましくない味や臭いを発生させないためのアリールスルファターゼ夾雑量を特定し、本発明を完成させた。 Prior to solving the above problems, the present inventors selected a highly sensitive fluorescence method as a method for measuring arylsulfatase activity, examined appropriate measurement conditions, and established a measurement method. And by the method for measuring the activity of arylsulfatase, arylsulfatase is used for measuring the activity of arylsulfatase in a region that has been conventionally below the detection limit, so as not to generate an unpleasant taste or smell in milk or dairy products. The amount of contamination was identified and the present invention was completed.
 即ち本発明は、ラクターゼ遺伝子を有し且つアリールスルファターゼ蛋白の発現が制限されている酵母の二倍体菌株又は酵母のラクターゼ遺伝子が導入され且つアリールスルファターゼ蛋白の発現が制限されている遺伝子組換え微生物の培養液を原料として製造されたラクターゼ製剤であって、FCC IV法によるラクターゼ活性(単位:NLU/g)を基準として、下記の方法で測定し、計算したアリールスルファターゼ活性(単位:U/g)が0.1%以下であることを特徴とするラクターゼ製剤に関する:
(アリールスルファターゼ活性の測定方法)
(1)アリールスルファターゼの存在が予測される検体を、0.5N塩化カリウムを含む100mMリン酸カリウム緩衝液(pH6.5)で適宜希釈し、サンプルとする。
(2)4-メチルウンベリフェロンスルフェイトカリウムを2mM濃度で含有する水溶液を調製する。
(3)サンプルと4-メチルウンベリフェロンスルフェイトカリウム水溶液とを、1:1(容量基準)で混合し、37℃にて3時間反応させる。
(4)反応液に、反応液と同量(容量基準)の0.1N水酸化ナトリウム水溶液を添加し、反応を停止させ、測定用サンプルとする。
(5)励起波長360nm、蛍光波長450nmにて、蛍光強度を測定する。
(6)4-メチルウンベリフェロンを、0.5N塩化カリウムを含む100mMリン酸カリウム緩衝液(pH6.5)に溶解させ、適切な濃度の溶液とし、(4)と同様に0.1N水酸化ナトリウム水溶液を添加し、(5)と同様の条件で蛍光強度を測定する。
(7)(6)より、検量線を作成する。
(8)(5)で測定された蛍光強度と(7)で作成された検量線から、測定用サンプルの4-メチルウンベリフェロン濃度を算出し、それを3で割り、反応時間が1時間であった場合の4-メチルウンベリフェロン濃度を求める。さらに、反応液の容量から、1時間の反応中に生じた4-メチルウンベリフェロン量を算出する。
(9)こうして算出された4-メチルウンベリフェロン量は、(1)で調製したサンプルに含有されていた検体量に基づくものであるので、検体1g当たりの4-メチルウンベリフェロン量に換算する。
(10)基質と酵素との反応時間1時間あたりの4-メチルウンベリフェロン生成量が1nmoleであった場合を1ユニット(U)とし、単位は、検体、即ち酵素製剤1g当たりのユニット量、即ち「ユニット(U)/g」で表す。
That is, the present invention relates to a yeast diploid strain having a lactase gene and restricted expression of arylsulfatase protein, or a recombinant microorganism into which a yeast lactase gene has been introduced and expression of arylsulfatase protein is restricted. A lactase preparation produced from the above culture broth as a raw material, and the arylsulfatase activity (unit: U / g) measured and calculated by the following method based on the lactase activity (unit: NLU / g) by the FCC IV method. ) For lactase preparations characterized in that they are 0.1% or less:
(Measurement method of arylsulfatase activity)
(1) A specimen in which the presence of arylsulfatase is predicted is appropriately diluted with a 100 mM potassium phosphate buffer (pH 6.5) containing 0.5 N potassium chloride to prepare a sample.
(2) An aqueous solution containing 2-methylumbelliferone sulfate potassium at a concentration of 2 mM is prepared.
(3) The sample and a 4-methylumbelliferone sulfate aqueous solution are mixed at 1: 1 (volume basis) and reacted at 37 ° C. for 3 hours.
(4) To the reaction solution, add the same amount (volume basis) of 0.1N sodium hydroxide aqueous solution as the reaction solution to stop the reaction and prepare a measurement sample.
(5) The fluorescence intensity is measured at an excitation wavelength of 360 nm and a fluorescence wavelength of 450 nm.
(6) 4-Methylumbelliferone is dissolved in a 100 mM potassium phosphate buffer (pH 6.5) containing 0.5N potassium chloride to obtain a solution with an appropriate concentration. An aqueous sodium oxide solution is added, and the fluorescence intensity is measured under the same conditions as in (5).
(7) A calibration curve is created from (6).
(8) From the fluorescence intensity measured in (5) and the calibration curve created in (7), the 4-methylumbelliferone concentration of the measurement sample is calculated, divided by 3, and the reaction time is 1 hour. If so, determine the 4-methylumbelliferone concentration. Further, the amount of 4-methylumbelliferone generated during the reaction for 1 hour is calculated from the volume of the reaction solution.
(9) Since the amount of 4-methylumbelliferone calculated in this way is based on the amount of sample contained in the sample prepared in (1), it is converted to the amount of 4-methylumbelliferone per gram of sample. To do.
(10) The case where the amount of 4-methylumbelliferone produced per 1 hour of the reaction time between the substrate and the enzyme is 1 nmole is defined as 1 unit (U), and the unit is the unit amount per 1 g of the specimen, that is, the enzyme preparation, That is, it is represented by “unit (U) / g”.
 工程(10)における「基質」とは4-メチルウンベリフェロンスルフェイトカリウムであり、「酵素」とはアリールスルファターゼである。 In step (10), “substrate” is potassium 4-methylumbelliferone sulfate, and “enzyme” is arylsulfatase.
 上記の本発明において、「アリールスルファターゼ蛋白の発現が制限されている」とは、例えば、アリールスルファターゼ遺伝子(構造遺伝子)が破壊されていたり、アリールスルファターゼ遺伝子にアリールスルファターゼ蛋白を発現させるように働く発現調節遺伝子が破壊されていたり、あるいはアリールスルファターゼ遺伝子及び/又はアリールスルファターゼ蛋白発現調節遺伝子を有さないために、アリールスルファターゼ蛋白が生成されないか又はその生成量が低減されていることをいう。アリールスルファターゼ蛋白の発現がない、すなわち生成量がゼロであることが好ましいが、アリールスルファターゼ活性(単位:U/g)/ラクターゼ活性(単位:NLU/g)が0.1%以下となるように、好ましくは0.02%以下となるように、アリールスルファターゼ蛋白の発現が制限されていればよい。 In the present invention described above, “expression of arylsulfatase protein is restricted” means, for example, an expression in which the arylsulfatase gene (structural gene) is disrupted or the arylsulfatase gene functions to express the arylsulfatase protein It means that the arylsulfatase protein is not produced or the production amount thereof is reduced because the regulatory gene is disrupted or the arylsulfatase gene and / or the arylsulfatase protein expression regulatory gene is not present. It is preferable that the arylsulfatase protein is not expressed, that is, the production amount is zero, but the arylsulfatase activity (unit: U / g) / lactase activity (unit: NLU / g) is 0.1% or less. However, the expression of the arylsulfatase protein may be limited so as to be preferably 0.02% or less.
 また、本発明に係るラクターゼ製剤は、そのラクターゼ活性が1,000NLU/g以上であることが好ましく、2,000NLU/g以上であることがさらに好ましく、3,000NLU/g以上であることがさらにより好ましく、4,000NLU/g以上であることが特に好ましく、5,000NLU/g以上であることが最も好ましい。 The lactase preparation according to the present invention preferably has a lactase activity of 1,000 NLU / g or more, more preferably 2,000 NLU / g or more, and further preferably 3,000 NLU / g or more. More preferably, it is more preferably 4,000 NLU / g or more, and most preferably 5,000 NLU / g or more.
 ラクターゼ遺伝子を有し且つアリールスルファターゼ蛋白の発現が制限されている酵母の二倍体菌株は、酵母の二倍体菌株の変異処理によって取得された変異株であってもよいし、酵母の二倍体菌株にアリールスルファターゼ遺伝子又はアリールスルファターゼ蛋白発現調節遺伝子の欠失操作を施して得られた変異株であってもよい。ラクターゼ蛋白の産生量が多い酵母の二倍体菌株を親株とする変異株が好ましい。 The yeast diploid strain having a lactase gene and restricted expression of arylsulfatase protein may be a mutant strain obtained by a mutation treatment of a yeast diploid strain or a yeast diploid strain. It may be a mutant obtained by subjecting a body strain to deletion of an arylsulfatase gene or an arylsulfatase protein expression regulatory gene. A mutant strain whose parent strain is a diploid strain of yeast having a large production amount of lactase protein is preferred.
 酵母の二倍体菌株は、クリベロマイセス・ラクティス(Kluyveromyces lactis)又はその近縁種であるクリベロマイセス・マリキシアヌス(Kluyveromyces marxianus)の二倍体菌株であることが好ましい。また、酵母のラクターゼ遺伝子が導入され且つアリールスルファターゼ蛋白の発現が制限されている遺伝子組換え微生物は、クリベロマイセス・ラクティス又はクリベロマイセス・マリキシアヌスのラクターゼ遺伝子が導入された遺伝子組換え微生物であることが好ましい。 The diploid strain of yeast is preferably a diploid strain of Kluyveromyces lactis or its closely related species, Kluyveromyces marxianus. In addition, the genetically modified microorganism into which the yeast lactase gene is introduced and the expression of the arylsulfatase protein is restricted is preferably a genetically modified microorganism into which the Klaveromyces lactis or Kriveromyces marixianus lactase gene is introduced.
 本発明は、ラクターゼ遺伝子を有し且つアリールスルファターゼ蛋白の発現が制限されている酵母の二倍体菌株又は酵母のラクターゼ遺伝子が導入され且つアリールスルファターゼ蛋白の発現が制限されている遺伝子組換え微生物を培養し、細胞壁を破壊し又は破壊せずに培養液を回収し、ラクターゼ製剤を調製することを特徴とするラクターゼ製剤の製造方法にも関する。なお、細胞壁を破壊せずに培養液を回収する場合とは、遺伝子組換え微生物がラクターゼを分泌する場合である。 The present invention relates to a yeast diploid strain having a lactase gene and restricted expression of an arylsulfatase protein, or a genetically modified microorganism into which a yeast lactase gene has been introduced and the expression of an arylsulfatase protein is restricted. The present invention also relates to a method for producing a lactase preparation, which comprises culturing, recovering a culture solution with or without destroying cell walls, and preparing a lactase preparation. The case where the culture solution is collected without destroying the cell wall is a case where the genetically modified microorganism secretes lactase.
 ラクターゼ製剤の調製工程には、ラクターゼ蛋白の濃縮、夾雑物の除去等の、当技術分野で行われている精製工程が包含され得る。また、製造されるラクターゼ製剤は、例えば、上記の本発明に係る活性測定方法によるアリールスルファターゼ活性(単位:U/g)/FCC IV法によるラクターゼ活性(単位:NLU/g)が0.1%以下である。 The preparation process of the lactase preparation may include purification steps performed in the art, such as concentration of lactase protein and removal of contaminants. The produced lactase preparation has, for example, an arylsulfatase activity (unit: U / g) according to the activity measuring method according to the present invention described above / a lactase activity (unit: NLU / g) by the FCC IV method of 0.1%. It is as follows.
 さらに、本発明は、本発明に係るラクターゼ製剤を用いて製造されたことを特徴とする乳製品に関する。 Furthermore, the present invention relates to a dairy product produced using the lactase preparation according to the present invention.
 高感度なアリールスルファターゼ活性測定方法が確立されたため、ラクターゼ製剤中のアリールスルファターゼ量をその活性を指標として正確に把握することが可能となった。また、ラクターゼ遺伝子を有し且つアリールスルファターゼ蛋白の発現が制限されている酵母の二倍体菌株又は酵母のラクターゼ遺伝子が導入され且つアリールスルファターゼ遺伝子蛋白の発現が制限されている遺伝子組換え微生物の培養液を原料として、アリールスルファターゼ夾雑量がごく微量であるか又はアリールスルファターゼを含有しないラクターゼ製剤を提供することが可能となった。本発明のラクターゼ製剤を使用すれば、ロングライフミルク等において、違和感のある好ましくない味や臭いの発生が抑制されるという効果が得られる。 Since a highly sensitive method for measuring arylsulfatase activity has been established, it has become possible to accurately grasp the amount of arylsulfatase in a lactase preparation using the activity as an index. In addition, a diploid strain of yeast having a lactase gene and restricted expression of arylsulfatase protein, or cultivation of a genetically modified microorganism into which yeast lactase gene is introduced and expression of arylsulfatase gene protein is restricted By using the liquid as a raw material, it has become possible to provide a lactase preparation containing a very small amount of arylsulfatase contamination or no arylsulfatase. If the lactase preparation of the present invention is used, the effect of suppressing the occurrence of an unpleasant taste and unpleasant taste in long life milk and the like can be obtained.
比色法によるアリールスルファターゼ活性の測定結果を示すグラフである。It is a graph which shows the measurement result of the aryl sulfatase activity by a colorimetric method. 蛍光法によるアリールスルファターゼ活性の測定結果を示すグラフである。It is a graph which shows the measurement result of the arylsulfatase activity by a fluorescence method. アリールスルファターゼ遺伝子破壊ベクターpdSuC1の構築方法を示す模式図である。It is a schematic diagram which shows the construction method of the arylsulfatase gene disruption vector pdSuC1. アリールスルファターゼ遺伝子破壊ベクターpdSuCM6の構築方法を示す模式図である。It is a schematic diagram which shows the construction method of the arylsulfatase gene disruption vector pdSuCM6. 二つのアリールスルファターゼ遺伝子破壊ベクターの導入方法を示す模式図である。It is a schematic diagram showing a method for introducing two arylsulfatase gene disruption vectors. アリールスルファターゼ遺伝子二つを含む株、一つのアリールスルファターゼ遺伝子が破壊された株、及び二つのアリールスルファターゼ遺伝子が破壊された株のサザン・ブロッティングの結果を示す写真である。It is a photograph showing the results of Southern blotting of a strain containing two arylsulfatase genes, a strain in which one arylsulfatase gene was disrupted, and a strain in which two arylsulfatase genes were disrupted.
 初めに、アリールスルファターゼの活性測定方法について説明する。 First, a method for measuring the activity of arylsulfatase will be described.
 アリールスルファターゼの活性測定方法として従来から知られている方法は、p-ニトロフェノールのような発色団に硫酸基が結合した化合物を基質として使用する比色法である。この方法では、基質とアリールスルファターゼとの反応によって基質から硫酸基が外れて遊離する発色団の量を、吸光度により測定する。ただし、p-ニトロフェノール等の発色団の遊離量が少ない場合には、吸光度の変化は少なく、明確な測定値を得ることが困難である。 A conventionally known method for measuring the activity of arylsulfatase is a colorimetric method using a compound in which a sulfate group is bound to a chromophore such as p-nitrophenol as a substrate. In this method, the amount of chromophore released by the removal of sulfate groups from the substrate due to the reaction between the substrate and arylsulfatase is measured by absorbance. However, when the amount of liberated chromophore such as p-nitrophenol is small, the change in absorbance is small and it is difficult to obtain a clear measured value.
 アリールスルファターゼの活性測定方法として、また、蛍光団に硫酸基を結合させた化合物、例えば4-メチルウンベリフェリル硫酸を基質として用いる蛍光法も知られている。蛍光法の感度は、一般的に、比色法の感度の100倍以上であるといわれている。そこで、本発明者等は、アリールスルファターゼ活性を測定するための蛍光法について、基質と酵素との反応条件や測定条件を検討し、感度の高い測定方法を確立した。この高感度活性測定方法の実施により、ラクターゼ製剤中に夾雑するアリールスルファターゼの量を正確に把握することができるようになった。その結果として、アリールスルファターゼ含有量がゼロ又は極く少量のラクターゼ製剤を提供することが可能となった。 As a method for measuring the activity of arylsulfatase, a fluorescence method using a compound in which a sulfate group is bound to a fluorophore, such as 4-methylumbelliferyl sulfate, as a substrate is also known. The sensitivity of the fluorescence method is generally said to be at least 100 times that of the colorimetric method. Therefore, the present inventors have examined the reaction conditions and measurement conditions between the substrate and the enzyme and established a highly sensitive measurement method for the fluorescence method for measuring arylsulfatase activity. By carrying out this highly sensitive activity measurement method, the amount of arylsulfatase contaminated in the lactase preparation can be accurately grasped. As a result, it has become possible to provide lactase preparations having zero or very little arylsulfatase content.
 本発明に係るアリールスルファターゼの活性測定方法は、次の通りである。 The method for measuring the activity of arylsulfatase according to the present invention is as follows.
(1)アリールスルファターゼの存在が予測される検体を、0.5N塩化カリウムを含む100mMリン酸カリウム緩衝液(pH6.5)で適宜希釈し、サンプルとする。
(2)4-メチルウンベリフェロンスルフェイトカリウムを2mM濃度で含有する水溶液を調製する。
(3)サンプルと4-メチルウンベリフェロンスルフェイトカリウム水溶液とを、1:1(容量基準)で混合し、37℃にて3時間反応させる。
(4)反応液に、反応液と同量(容量基準)の0.1N水酸化ナトリウム水溶液を添加し、反応を停止させ、測定用サンプルとする。
(5)励起波長360nm、蛍光波長450nmにて、蛍光強度を測定する。
(6)4-メチルウンベリフェロンを、0.5N塩化カリウムを含む100mMリン酸カリウム緩衝液(pH6.5)に溶解させ、適切な濃度の溶液とし、(4)と同様に0.1N水酸化ナトリウム水溶液を添加し、(5)と同様の条件で蛍光強度を測定する。
(7)(6)より、検量線を作成する。
(8)(5)で測定された蛍光強度と(7)で作成された検量線から、測定用サンプルの4-メチルウンベリフェロン濃度を算出し、それを3で割り、反応時間が1時間であった場合の4-メチルウンベリフェロン濃度を求める。さらに、反応液の容量から、1時間の反応中に生じた4-メチルウンベリフェロン量を算出する。
(9)こうして算出された4-メチルウンベリフェロン量は、(1)で調製したサンプルに含有されていた検体量に基づくものであるので、検体1g当たりの4-メチルウンベリフェロン量に換算する。
(10)基質と酵素との反応時間1時間あたりの4-メチルウンベリフェロン生成量が1nmoleであった場合を1ユニット(U)とし、単位は、検体、即ち酵素製剤1g当たりのユニット量、即ち「ユニット(U)/g」で表す。
(1) A specimen in which the presence of arylsulfatase is predicted is appropriately diluted with a 100 mM potassium phosphate buffer (pH 6.5) containing 0.5 N potassium chloride to prepare a sample.
(2) An aqueous solution containing 2-methylumbelliferone sulfate potassium at a concentration of 2 mM is prepared.
(3) The sample and a 4-methylumbelliferone sulfate aqueous solution are mixed at 1: 1 (volume basis) and reacted at 37 ° C. for 3 hours.
(4) To the reaction solution, add the same amount (volume basis) of 0.1N sodium hydroxide aqueous solution as the reaction solution to stop the reaction and prepare a measurement sample.
(5) The fluorescence intensity is measured at an excitation wavelength of 360 nm and a fluorescence wavelength of 450 nm.
(6) 4-Methylumbelliferone is dissolved in a 100 mM potassium phosphate buffer (pH 6.5) containing 0.5N potassium chloride to obtain a solution with an appropriate concentration. An aqueous sodium oxide solution is added, and the fluorescence intensity is measured under the same conditions as in (5).
(7) A calibration curve is created from (6).
(8) From the fluorescence intensity measured in (5) and the calibration curve created in (7), the 4-methylumbelliferone concentration of the measurement sample is calculated, divided by 3, and the reaction time is 1 hour. If so, determine the 4-methylumbelliferone concentration. Further, the amount of 4-methylumbelliferone generated during the reaction for 1 hour is calculated from the volume of the reaction solution.
(9) Since the amount of 4-methylumbelliferone calculated in this way is based on the amount of sample contained in the sample prepared in (1), it is converted to the amount of 4-methylumbelliferone per gram of sample. To do.
(10) The case where the amount of 4-methylumbelliferone produced per 1 hour of the reaction time between the substrate and the enzyme is 1 nmole is defined as 1 unit (U), and the unit is the unit amount per 1 g of the specimen, that is, the enzyme preparation, That is, it is represented by “unit (U) / g”.
 本発明に係るラクターゼ製剤は、上記の方法で測定し、計算したアリールスルファターゼ活性が、FCC IV法(Food Chemicals Codex Fourth Edition, Effective July 1, 1996, Committee on Food Chemicals odex p.p.801-802)によるラクターゼ活性(単位:NLU/g)を基準として、0.1%以下であり、好ましくは0.02%以下である。 The lactase preparation according to the present invention was measured by the above method, and the calculated arylsulfatase activity was determined by the FCC IV method (Food Chemicals Codex Fourth Edition, Effective Jury 1, 1996, Committee on Food 2 Chemical 80. Chemp. 80 ) Based on lactase activity (unit: NLU / g), it is 0.1% or less, preferably 0.02% or less.
 本発明のラクターゼ製剤の製造には、ラクターゼ蛋白を生成する、ラクターゼ遺伝子を有し且つアリールスルファターゼ蛋白の発現が制限されている酵母の二倍体菌株を用いる。このような酵母の二倍体菌株は、例えば、微生物の変異処理によって取得された変異株である。このような変異株は、例えば、紫外線照射や化学的突然変異誘発物質に酵母を暴露させて変異処理を行い、二倍体の両遺伝子について、アリールスルファターゼ遺伝子やアリールスルファターゼ蛋白の発現調節遺伝子を破壊又は欠失させる方法や、二倍体の両遺伝子について、アリールスルファターゼ遺伝子やアリールスルファターゼ蛋白の発現調節遺伝子を遺伝子工学的手法により欠失させる方法等によって得ることが出来る。なお、所望の変異株が得られたか否かは、本発明に係るアリールスルファターゼ活性測定方法(蛍光法)で、変異後の酵母の培養液のアリールスルファターゼ活性を測定すればよい。 In the production of the lactase preparation of the present invention, a diploid strain of yeast that produces lactase protein, has a lactase gene, and is restricted in the expression of arylsulfatase protein is used. Such a yeast diploid strain is, for example, a mutant strain obtained by microbial mutation treatment. For example, such mutant strains can be treated by exposing yeast to UV irradiation or chemical mutagens to destroy the arylsulfatase gene or the arylsulfatase protein expression regulatory gene for both diploid genes. Alternatively, it can be obtained by a deletion method, a method of deleting an arylsulfatase gene or an expression regulator gene of an arylsulfatase protein by genetic engineering techniques, etc. for both diploid genes. Whether or not a desired mutant strain has been obtained may be determined by measuring the arylsulfatase activity of the cultivated yeast culture solution by the method for measuring arylsulfatase activity (fluorescence method) according to the present invention.
 紫外線による突然変異の誘発は、例えば二倍体酵母の懸濁液に、紫外線を照射することによって行う。また、化学的突然変異の誘発は、例えば二倍体酵母の懸濁液に、化学的突然変異誘発物質を添加することによって行う。なお、化学的突然変異誘発物質の例としては、5-ブロモウラシル、2-アミノプリン、亜硝酸、ヒドロキシルアミン、アクリフラビン、メタンスルホン酸化合物、ニトロソグアニジン等が挙げられる。 Induction of mutation by ultraviolet rays is performed, for example, by irradiating a suspension of diploid yeast with ultraviolet rays. In addition, chemical mutagenesis is performed by adding a chemical mutagen to a suspension of diploid yeast, for example. Examples of chemical mutagens include 5-bromouracil, 2-aminopurine, nitrous acid, hydroxylamine, acriflavine, methanesulfonic acid compound, nitrosoguanidine and the like.
 アリールスルファターゼ遺伝子又はアリールスルファターゼ蛋白の発現調節遺伝子を遺伝子工学的手法により欠失させるには、欠失させるべき遺伝子の相同配列を有する遺伝子断片を取得し、その断片をベクターにサブクローニングして欠失させるべき遺伝子の破壊ベクターを構築し、そしてそのベクターを用いて酵母の二倍体菌株の形質転換を行う等の、通常の遺伝子工学的手法を適用すればよい。 In order to delete an arylsulfatase gene or an expression regulator gene of an arylsulfatase protein by genetic engineering techniques, a gene fragment having a homologous sequence of the gene to be deleted is obtained, and the fragment is subcloned into a vector and deleted. Ordinary genetic engineering techniques, such as constructing a disruption vector for a power gene and transforming a diploid strain of yeast using the vector, may be applied.
 本発明のラクターゼ製剤の製造には、酵母のラクターゼ遺伝子がラクターゼ蛋白を発現するように導入され且つアリールスルファターゼ蛋白の発現が制限されている遺伝子組換え微生物も用いることが出来る。前記したように、「アリールスルファターゼ蛋白の発現が制限されている」とは、例えば、アリールスルファターゼ蛋白の生成に関わる遺伝子が制限されているために、より具体的には、アリールスルファターゼ遺伝子及び/又はアリールスルファターゼ蛋白発現調節遺伝子を有さないために、あるいはアリールスルファターゼ遺伝子(構造遺伝子)が破壊されていたり、アリールスルファターゼ遺伝子にアリールスルファターゼ蛋白を発現させるように働く発現調節遺伝子が破壊されているために、アリールスルファターゼ蛋白が生成されないか又はその生成量が低減されていることをいう。 In the production of the lactase preparation of the present invention, a recombinant microorganism into which a yeast lactase gene is introduced so as to express a lactase protein and the expression of an arylsulfatase protein is restricted can also be used. As described above, “expression of arylsulfatase protein is restricted” means that, for example, a gene involved in the production of arylsulfatase protein is restricted, and more specifically, arylsulfatase gene and / or Because there is no aryl sulfatase protein expression regulatory gene, or because the aryl sulfatase gene (structural gene) is disrupted or the expression regulatory gene that causes the aryl sulfatase gene to express the aryl sulfatase protein is disrupted It means that arylsulfatase protein is not produced or its production amount is reduced.
 酵母のラクターゼ遺伝子が導入され且つアリールスルファターゼ蛋白の発現が制限されている遺伝子組換え微生物は、公知の方法により調製することが出来る。例えば、薬剤Aに耐性を持つプラスミドにラクターゼ遺伝子を、必要な場合にはラクターゼ遺伝子の発現調節遺伝子も同時に、組み込む。このようにして調製されたラクターゼ発現プラスミドを用い、宿主となる微生物の形質転換を行う。形質転換後の微生物を、薬剤Aを含む培地で培養し、出現したコロニーを選択する。 A genetically modified microorganism into which a yeast lactase gene is introduced and the expression of arylsulfatase protein is restricted can be prepared by a known method. For example, a lactase gene is incorporated into a plasmid resistant to drug A and, if necessary, an expression control gene for the lactase gene is incorporated at the same time. The lactase expression plasmid thus prepared is used to transform a host microorganism. The transformed microorganism is cultured in a medium containing the drug A, and the appearing colonies are selected.
 酵母のラクターゼ遺伝子が導入され且つアリールスルファターゼ蛋白の発現が制限されている遺伝子組換え微生物を得るための宿主としては、大腸菌、酵母、枯草菌等を使用することが出来る。 E. coli, yeast, Bacillus subtilis, etc. can be used as a host for obtaining a genetically modified microorganism into which a yeast lactase gene has been introduced and the expression of arylsulfatase protein is restricted.
 酵母のラクターゼ遺伝子が導入され且つアリールスルファターゼ蛋白の発現が制限されている遺伝子組換え微生物を得るための宿主として、アリールスルファターゼ遺伝子やアリールスルファターゼ蛋白の発現調節遺伝子をもとより有しない宿主、もしくは、アリールスルファターゼ遺伝子やアリールスルファターゼ蛋白の発現調節遺伝子を破壊または欠失させた宿主が望ましい。 As a host for obtaining a recombinant microorganism into which a yeast lactase gene has been introduced and the expression of arylsulfatase protein is restricted, a host that does not have an arylsulfatase gene or an arylsulfatase protein expression regulatory gene, or an arylsulfatase A host in which a gene or an arylsulfatase protein expression regulatory gene is disrupted or deleted is desirable.
 ラクターゼ製剤用のラクターゼは、ラクターゼ遺伝子を有し且つアリールスルファターゼ蛋白の発現が制限されている酵母の二倍体菌株又は酵母のラクターゼ遺伝子が導入され且つアリールスルファターゼ蛋白の発現が制限されている遺伝子組換え微生物の培養液から精製する。なお、「培養液」の概念には、培養上清や回収菌体からの抽出液が含まれる。 A lactase for a lactase preparation is a yeast diploid strain that has a lactase gene and the expression of an arylsulfatase protein is restricted, or a gene set in which a yeast lactase gene is introduced and the expression of an arylsulfatase protein is restricted Purify from the culture solution of the replacement microorganism. Note that the concept of “culture solution” includes a culture supernatant and an extract from recovered cells.
 酵母等の微生物の培養には、フラスコ、ミニジャー、タンク等の培養器を用いることができ、培養条件としては、当該微生物による酵素生産に適する温度、pH、攪拌数等を選択する。 Incubation of microorganisms such as yeast can be performed using an incubator such as a flask, miniger, tank, etc. As culture conditions, a temperature, pH, number of stirring, etc. suitable for enzyme production by the microorganisms are selected.
 培養終了後、通常は細胞壁を破壊することによってラクターゼが溶解した培養液を得る。なお、培養に供された微生物がラクターゼを分泌する場合には、細胞壁の破壊を行わなくてもよい。 After completion of the culture, a culture solution in which lactase is dissolved is usually obtained by breaking the cell wall. In addition, when the microorganisms used for culture secrete lactase, the cell wall need not be destroyed.
 培養液は、通常、遠心分離、ろ過その他の本技術分野で通常行われている適切な方法をもって、培養上清と残渣とに分離される。培養上清は、そのまま酵素液として使用してもよいし、限外ろ過膜等を用いて濃縮した後、酵素液として使用してもよい。あるいは、培養液又は培養上清を、吸着、溶剤分画、硫安分画、クロマトグラフィー、結晶化等の精製操作の中の一つ以上に供して精製したものを、酵素液として使用してもよい。酵素液は、噴霧乾燥、凍結乾燥等の方法によって粉体化されてもよい。このようにして得られた酵素液そのものを、ラクターゼ製剤として使用することも出来る。 The culture solution is usually separated into a culture supernatant and a residue by an appropriate method usually used in this technical field, such as centrifugation, filtration, or the like. The culture supernatant may be used as it is as an enzyme solution, or may be used as an enzyme solution after being concentrated using an ultrafiltration membrane or the like. Alternatively, a culture solution or culture supernatant that has been purified by subjecting it to one or more purification operations such as adsorption, solvent fractionation, ammonium sulfate fractionation, chromatography, crystallization, etc. may be used as an enzyme solution. Good. The enzyme solution may be pulverized by a method such as spray drying or freeze drying. The enzyme solution itself thus obtained can also be used as a lactase preparation.
 本発明に係るラクターゼ製剤の必須構成成分は、ラクターゼである。ラクターゼ製剤には、ラクターゼの活性を阻害しないような物質であり且つ活性を阻害しないような量であれば、又は、ラクターゼ製剤の使用対象に対して望ましくない作用をしない限りは、その他の成分が存在していてもよい。存在していてもよい物質の例を挙げると、ラクターゼの安定化に寄与する金属塩類、各種糖類、アスコルビン酸、グリセリン等、使い勝手をよくするための賦形剤である澱粉、デキストリン、緩衝作用を有する無機塩類等である。ラクターゼ製剤の性状は特に限定されず、例えば、粉末、顆粒、溶液等であってよい。 The essential component of the lactase preparation according to the present invention is lactase. The lactase preparation contains other components as long as it is a substance that does not inhibit the activity of the lactase and does not inhibit the activity, or unless it has an undesirable effect on the intended use of the lactase preparation. May be present. Examples of substances that may be present include starches, dextrin, and buffering agents that are excipients for ease of use, such as metal salts that contribute to the stabilization of lactase, various sugars, ascorbic acid, glycerin, etc. Inorganic salts and the like. The properties of the lactase preparation are not particularly limited, and may be, for example, powder, granules, solutions and the like.
 本発明は、本発明に係るラクターゼ製剤を用いて製造された乳製品にも関する。乳製品とは、ロングライフ牛乳等の牛乳類、ヨーグルト、生クリーム、サワークリーム、チーズ等をいう。ラクターゼ製剤は、本技術分野における通常の方法や使用量で使用される。 The present invention also relates to a dairy product produced using the lactase preparation according to the present invention. Dairy products refer to milk such as long life milk, yogurt, fresh cream, sour cream, cheese and the like. The lactase preparation is used in a usual manner or use amount in this technical field.
 以下に、実施例により、本発明を具体的に説明する。 Hereinafter, the present invention will be described specifically by way of examples.
[実施例1]従来より知られている比色法でのアリールスルファターゼ活性の測定
 GODO-YNL2(合同酒精株式会社製ラクターゼ製剤)を蒸留水に溶解させ、1%(w/v)溶液を得た。この1%溶液を、0.5N塩化カリウムを含む100mMリン酸カリウム緩衝液(pH6.5)を用いて希釈し、0.8%(w/v)、0.6%(w/v)、0.4%(w/v)及び0.2%(w/v)溶液を得た。各溶液0.5mLに20mM p-ニトロフェニルスルフェイトの100mMリン酸カリウム緩衝液(pH6.5)溶液0.5mLを加え、37℃で3時間反応させた。これに1.5N水酸化ナトリウム水溶液1.5mLを加えて反応を停止させ、410nmにおける吸光度を測定した。
[Example 1] Measurement of arylsulfatase activity by a conventionally known colorimetric method GODO-YNL2 (Lactase preparation manufactured by Godo Shusei Co., Ltd.) is dissolved in distilled water to obtain a 1% (w / v) solution. It was. This 1% solution was diluted with 100 mM potassium phosphate buffer (pH 6.5) containing 0.5 N potassium chloride, 0.8% (w / v), 0.6% (w / v), 0.4% (w / v) and 0.2% (w / v) solutions were obtained. 0.5 mL of a 20 mM p-nitrophenyl sulfate solution in 100 mM potassium phosphate buffer (pH 6.5) was added to 0.5 mL of each solution and reacted at 37 ° C. for 3 hours. The reaction was stopped by adding 1.5 mL of a 1.5N aqueous sodium hydroxide solution, and the absorbance at 410 nm was measured.
 結果を図1に示す。比色法では、酵素製剤の1%(w/v)溶液では、アリールスルファターゼ活性はまったく測定できなかった。 The results are shown in FIG. In the colorimetric method, arylsulfatase activity could not be measured at all in a 1% (w / v) solution of the enzyme preparation.
[実施例2]蛍光法でのアリールスルファターゼ活性の測定
 GODO-YNL2(合同酒精株式会社製ラクターゼ製剤)を0.5N塩化カリウムを含む100mMリン酸カリウム緩衝液(pH6.5)に溶解させ、1%(w/v)溶液を得た。この1%溶液を、同緩衝液を用いて希釈し、0.8%(w/v)、0.6%(w/v)、0.4%(w/v)及び0.2%(w/v)溶液を得た。
Example 2 Measurement of Aryl Sulfatase Activity by Fluorescence Method GODO-YNL2 (Lactase preparation manufactured by Godo Sakesei Co., Ltd.) was dissolved in 100 mM potassium phosphate buffer (pH 6.5) containing 0.5 N potassium chloride. % (W / v) solution was obtained. This 1% solution was diluted with the same buffer and 0.8% (w / v), 0.6% (w / v), 0.4% (w / v) and 0.2% ( w / v) A solution was obtained.
 各溶液0.5mLに2mM 4-メチルウンベリフェリルスルフェイトカリウム水溶液0.5mL加え、37℃で3時間反応させた。これに0.1N水酸化ナトリウム水溶液1mLを加えて反応を停止させ、励起波長360nm、蛍光波長450nmにて蛍光強度を測定した。 0.5 mL of 2 mM 4-methylumbelliferyl sulfate aqueous solution was added to 0.5 mL of each solution and reacted at 37 ° C. for 3 hours. The reaction was stopped by adding 1 mL of a 0.1N sodium hydroxide aqueous solution, and the fluorescence intensity was measured at an excitation wavelength of 360 nm and a fluorescence wavelength of 450 nm.
 結果を図2に示す。蛍光法では、比色法とは異なり、濃度が1%(w/v)以下の酵素製剤溶液でも、良好な定量性を示した。 The results are shown in FIG. Unlike the colorimetric method, the fluorescence method showed good quantitativeness even with an enzyme preparation solution having a concentration of 1% (w / v) or less.
[実施例3]アリールスルファターゼ活性測定における比色法と蛍光法との比較
 アリールスルファターゼ活性測定における比色法と蛍光法との感度の相違を検討した。先ず、この実験で使用する精製ラクターゼを調製した。
[Example 3] Comparison between colorimetric method and fluorescence method in measuring arylsulfatase activity The difference in sensitivity between the colorimetric method and fluorescence method in measuring arylsulfatase activity was examined. First, purified lactase used in this experiment was prepared.
(精製ラクターゼの調製)
 GODO-YNL2(合同酒精株式会社製ラクターゼ製剤)50kgを、限外ろ過膜(旭化成株式会社製ACP膜)を用いてその導電率が3mSv以下となるまで加水脱塩した。これに水を加えて全量125Lとした。次いで、あらかじめ10mMリン酸カリウム緩衝液(pH7)にて平衡化しておいたイオン交換樹脂(トーソー株式会社製DEAEトヨパール650M、40cmφ、50L)に吸着させた。50mM塩化ナトリウムを含む10mMリン酸カリウム緩衝液(pH7)40Lにて洗浄し、次いで100mM塩化ナトリウムを含む10mMリン酸カリウム緩衝液(pH7)200Lでラクターゼを溶出させた。この際、フラクションを20Lずつに分画した。各フラクションのラクターゼ活性(FCC IV法による;Food Chemicals Codex Fourth Edition, Effective July 1, 1996, Committee on Food Chemicals odex p.p.801-802)及びアリールスルファターゼ活性(蛍光法による;詳細は下記のとおり)を測定し、アリールスルファターゼの低減した画分を回収、混合し、限外ろ過膜(旭化成株式会社製ACP膜)を用いて濃縮し、ラクターゼ濃縮液を得た。この濃縮液に50%(w/w)となるようグリセリンを加え、精製ラクターゼ製剤を得た。
(Preparation of purified lactase)
50 kg of GODO-YNL2 (Lactase preparation manufactured by Godo Seisei Co., Ltd.) was hydrolyzed and desalted using an ultrafiltration membrane (ACP membrane manufactured by Asahi Kasei Co., Ltd.) until the conductivity was 3 mSv or less. Water was added to make a total volume of 125L. Next, it was adsorbed on an ion exchange resin (DEAE Toyopearl 650M, 40 cmφ, 50 L, manufactured by Tosoh Corporation) that had been equilibrated in advance with 10 mM potassium phosphate buffer (pH 7). The plate was washed with 40 L of 10 mM potassium phosphate buffer (pH 7) containing 50 mM sodium chloride, and then lactase was eluted with 200 L of 10 mM potassium phosphate buffer (pH 7) containing 100 mM sodium chloride. At this time, the fraction was fractionated into 20 L portions. Lactase activity of each fraction (according to FCC IV method; Food Chemicals Codex Fourth Edition, Effective July 1, 1996, Committee on Food Chemicals p.801-802) and aryl sulfatase activity as described in detail below; ) Was collected, and the fraction in which arylsulfatase was reduced was collected, mixed, and concentrated using an ultrafiltration membrane (ACP membrane manufactured by Asahi Kasei Corporation) to obtain a lactase concentrate. Glycerin was added to this concentrated solution to 50% (w / w) to obtain a purified lactase preparation.
 GODO-YNL2と、上記のようにして調製された精製ラクターゼ製剤であっていずれもFCC IV法によるラクターゼ活性が5000乃至5500NLU/gであるものについて、アリールスルファターゼ活性(蛍光法;詳細は下記のとおり)を測定したところ、精製ラクターゼ製剤のアリールスルファターゼ活性は、精製前の1/840であった(後記表1を参照のこと)。 With regard to GODO-YNL2 and purified lactase preparations prepared as described above, both of which have lactase activity of 5000 to 5500 NLU / g by the FCC IV method, arylsulfatase activity (fluorescence method; details are as follows) ), The arylsulfatase activity of the purified lactase preparation was 1/840 before purification (see Table 1 below).
(様々なアリールスルファターゼ夾雑率の酵素製剤の調製)
 上記のようにして調製した精製ラクターゼ製剤と、GODO-YNL2を適宜混合して、様々なアリールスルファターゼ夾雑率のラクターゼ製剤を調製し、ラクターゼ活性(FCC IV法による)とアリールスルファターゼ活性(比色法及び蛍光法による)とを測定した。
(Preparation of enzyme preparations with various arylsulfatase contamination rates)
The purified lactase preparation prepared as described above and GODO-YNL2 are appropriately mixed to prepare lactase preparations with various arylsulfatase contamination rates, and lactase activity (by FCC IV method) and arylsulfatase activity (colorimetric method) And by fluorescence method).
(比色法でのアリールスルファターゼ活性の測定)
 ラクターゼ製剤0.5mLに20mM p-ニトロフェニルスルフェイトの100mMリン酸カリウム緩衝液(pH6.5)溶液0.5mLを加え、37℃で3時間反応させた。これに1.5N水酸化ナトリウム水溶液1.5mLを加えて反応を停止させ、410nmにおける吸光度を測定した。
(Measurement of arylsulfatase activity by colorimetric method)
0.5 mL of a 20 mM p-nitrophenyl sulfate solution in 100 mM potassium phosphate buffer (pH 6.5) was added to 0.5 mL of the lactase preparation and reacted at 37 ° C. for 3 hours. The reaction was stopped by adding 1.5 mL of a 1.5N aqueous sodium hydroxide solution, and the absorbance at 410 nm was measured.
 別途、p-ニトロフェノールを0乃至0.5mMの濃度で含有する水溶液を用意した。これらの各溶液0.5mLに100mMリン酸カリウム緩衝液(pH6.5)溶液0.5mLを加え、さらに1.5N水酸化ナトリウム水溶液1.5mLを加えて測定用サンプルを得た。410nmにおける吸光度を測定し、検量線を作成した。 Separately, an aqueous solution containing p-nitrophenol at a concentration of 0 to 0.5 mM was prepared. 0.5 mL of a 100 mM potassium phosphate buffer solution (pH 6.5) was added to 0.5 mL of each of these solutions, and 1.5 mL of a 1.5N sodium hydroxide aqueous solution was further added to obtain a measurement sample. Absorbance at 410 nm was measured to prepare a calibration curve.
 検量線から、反応液1mL中に含有されているp-ニトロフェノールの濃度を求め、さらに3で割り(反応時間が3時間であるため)、反応時間が1時間である場合のp-ニトロフェノールの濃度を算出した。次いで、この濃度から、反応液1mL中に含有されているp-ニトロフェノールの量を算出(単位:nmole)し、さらに2倍(ラクターゼ製剤使用量は0.5gであり、これを1g当たりに換算するため)することにより、アリールスルファターゼ活性を算出した。1Uは、1時間に1nmoleのp-ニトロフェノールを生成させる活性であり、アリールスルファターゼ活性は、単位「U/g-酵素製剤」で表される。 From the calibration curve, determine the concentration of p-nitrophenol contained in 1 mL of the reaction solution, and further divide by 3 (because the reaction time is 3 hours) to obtain p-nitrophenol when the reaction time is 1 hour. The concentration of was calculated. Next, from this concentration, the amount of p-nitrophenol contained in 1 mL of the reaction solution was calculated (unit: nmole), and further doubled (the amount of lactase preparation used was 0.5 g, and this amount per 1 g) The aryl sulfatase activity was calculated by the calculation. 1 U is an activity that generates 1 nmole of p-nitrophenol per hour, and arylsulfatase activity is expressed in units of “U / g-enzyme preparation”.
(蛍光法でのアリールスルファターゼ活性の測定)
 ラクターゼ製剤を0.5N塩化カリウムを含む100mMリン酸カリウム緩衝液(pH6.5)で希釈し、1%(w/v)溶液を得た。この1%溶液0.5mLに2mM 4-メチルウンベリフェリルスルフェイトカリウム水溶液0.5mL加え、37℃で3時間反応させた。これに0.1N水酸化ナトリウム水溶液1mLを加えて反応を停止させ、励起波長360nm、蛍光波長450nmにて蛍光強度を測定した。
(Measurement of arylsulfatase activity by fluorescence method)
The lactase preparation was diluted with a 100 mM potassium phosphate buffer (pH 6.5) containing 0.5N potassium chloride to obtain a 1% (w / v) solution. 0.5 mL of 2 mM 4-methylumbelliferyl sulfate aqueous solution was added to 0.5 mL of this 1% solution and reacted at 37 ° C. for 3 hours. The reaction was stopped by adding 1 mL of a 0.1N sodium hydroxide aqueous solution, and the fluorescence intensity was measured at an excitation wavelength of 360 nm and a fluorescence wavelength of 450 nm.
 別途、4-メチルウンベリフェロンを0乃至4μMの濃度で含有する0.5N塩化カリウムを含む100mMリン酸カリウム緩衝液(pH6.5)を用意した。これらの各溶液1.0mLに0.1N水酸化ナトリウム水溶液1mLを加えて測定用サンプルを得た。励起波長360nm、蛍光波長450nmにて蛍光強度を測定し、検量線を作成した。 Separately, a 100 mM potassium phosphate buffer (pH 6.5) containing 0.5N potassium chloride containing 4-methylumbelliferone at a concentration of 0 to 4 μM was prepared. A sample for measurement was obtained by adding 1 mL of a 0.1 N aqueous sodium hydroxide solution to 1.0 mL of each of these solutions. The fluorescence intensity was measured at an excitation wavelength of 360 nm and a fluorescence wavelength of 450 nm to prepare a calibration curve.
 検量線から、反応液1mL中に含有されている4-メチルウンベリフェロンの濃度を求め、さらに3で割り(反応時間が3時間であるため)、反応液の容量から反応中に生成した4-メチルウンベリフェロンの絶対量を算出した。さらに200倍(ラクターゼ製剤使用量は0.5×0.01=0.005gであり、これを検体(ラクターゼ製剤)1g当たりに換算するため)することにより、アリールスルファターゼ活性を算出した。1Uは、1時間に1nmoleの4-メチルウンベリフェロンを生成させる活性であり、アリールスルファターゼ活性は、単位「U/g-酵素製剤」で表される。 From the calibration curve, determine the concentration of 4-methylumbelliferone contained in 1 mL of the reaction solution, and further divide by 3 (because the reaction time is 3 hours). -The absolute amount of methylumbelliferone was calculated. Furthermore, the arylsulfatase activity was calculated by 200 times (the amount of lactase preparation used was 0.5 × 0.01 = 0.005 g, which was converted to 1 g of the sample (lactase preparation)). 1 U is an activity that produces 1 nmole of 4-methylumbelliferone per hour, and arylsulfatase activity is expressed in units of “U / g-enzyme preparation”.
(結果)
 結果を表1に示す。比色法では、アリールスルファターゼの含有量が少なくなると、測定することができなかったが、蛍光法では、比色法の測定限界の約1/100の濃度域まで正確に測定することができた。
(result)
The results are shown in Table 1. In the colorimetric method, measurement could not be performed when the content of arylsulfatase decreased, but in the fluorescence method, it was possible to accurately measure to a concentration range of about 1/100 of the measurement limit of the colorimetric method. .
Figure JPOXMLDOC01-appb-T000001
Figure JPOXMLDOC01-appb-T000001
[実施例4]アリールスルファターゼ活性測定における蛍光法とWO07/060247(特表2009-517061)に記載の方法との比較と、風味官能試験(その1)
 WO07/060247には、夾雑するアリールスルファターゼが19単位(WO07/060247において規定された単位)以下のラクターゼ製剤は、牛乳の滅菌後に乳糖を分解させるために添加された場合に異臭を生じさせない旨が記載されている。しかし、これは、ラクターゼの反応日数を2日間と限定して行った試験の結果に基づく見解である。一方、現実のロングライフミルクにラクターゼ製剤を添加した場合、1ヶ月以上の長期にわたって酵素反応が進行すると考えられる。そこで、様々な夾雑率でアリールスルファターゼを含有するラクターゼ製剤を調製し、それらを牛乳に添加し、所定の日数経過後に風味の確認を行った。
[Example 4] Comparison of fluorescence method for measuring arylsulfatase activity with the method described in WO07 / 060247 (Special Table 2009-517061) and taste sensory test (Part 1)
WO07 / 060247 states that a lactase preparation having 19 or less contaminating arylsulfatases (units defined in WO07 / 060247) does not produce off-flavors when added to decompose lactose after sterilization of milk. Are listed. However, this is a view based on the results of a test conducted by limiting the reaction days of lactase to 2 days. On the other hand, when a lactase preparation is added to actual long life milk, it is considered that the enzyme reaction proceeds over a long period of one month or longer. Therefore, lactase preparations containing arylsulfatase at various contamination rates were prepared, added to milk, and the flavor was confirmed after a predetermined number of days.
(様々なアリールスルファターゼ夾雑率のラクターゼ製剤の調製)
 様々な夾雑量のアリールスルファターゼを含有するラクターゼ製剤A乃至Eは、実施例3で調製した精製ラクターゼ製剤と、選択されたアリールスルファターゼ活性を100単位(WO07/060247に記載の単位)含むGODO-YNL2を適宜混合して調製した。
(Preparation of lactase preparations with various arylsulfatase contamination rates)
Lactase preparations A to E containing various contaminating amounts of arylsulfatase include the purified lactase preparation prepared in Example 3 and GODO-YNL2 containing 100 units of the selected arylsulfatase activity (units described in WO07 / 060247). Were mixed as appropriate.
 調製されたラクターゼ製剤A~Eのアリールスルファターゼ活性を、WO07/060247に記載の方法と、実施例3に示した蛍光法で測定した。また、ラクターゼ活性をFCC IV法で測定した。結果を表2に示す。ここで、WO07/060247に記載の単位とは、△OD410×10/時間/NLUのことである。 The arylsulfatase activities of the prepared lactase preparations A to E were measured by the method described in WO07 / 060247 and the fluorescence method shown in Example 3. Moreover, the lactase activity was measured by FCC IV method. The results are shown in Table 2. Here, the unit described in WO07 / 060247 is ΔOD 410 × 10 6 / hour / NLU.
Figure JPOXMLDOC01-appb-T000002
Figure JPOXMLDOC01-appb-T000002
(風味官能試験)
 WO07/060247の実施例4を参照し、市販牛乳(加熱殺菌したもの;殺菌条件:130℃ 2秒)に、ラクターゼが20000NLU/L-牛乳となるように、ラクターゼ製剤A~Eの各々を加え、30℃に保存した。保存2日後、1ヶ月後、及び3ヶ月後に、ラクターゼ製剤を添加していない牛乳とラクターゼ製剤を添加した牛乳の風味官能試験を行った。
(Flavor sensory test)
Referring to Example 4 of WO07 / 060247, each of lactase preparations A to E was added to commercially available milk (heat pasteurized; pasteurized conditions: 130 ° C. for 2 seconds) so that lactase was 20000 NLU / L-milk. And stored at 30 ° C. After 2 days of storage, after 1 month, and after 3 months, a flavor sensory test was conducted on milk not added with lactase preparation and milk added with lactase preparation.
 風味官能試験は、盲検試験で実施した。11~13人のパネラーが、一定期間保存後の牛乳の臭いを嗅ぎ、さらには口に含み、違和感のある臭いの有無を判断した。臭いを感じないものを0点(-)、感じるものを1点(+)、強く感じるものを2点(++)として採点して評価を行った。まとめた結果を表3に示す。 The flavor sensory test was conducted as a blind test. Eleven to thirteen panelists sniffed the milk after storage for a certain period of time, and also judged whether it had a smell that was uncomfortable and contained in the mouth. The evaluation was made with a score of 0 (-) for those that did not feel odor, 1 (+) for those that felt odor, and 2 (++) for those that felt strong. The summarized results are shown in Table 3.
Figure JPOXMLDOC01-appb-T000003
Figure JPOXMLDOC01-appb-T000003
 ラクターゼ製剤による反応期間(即ち、牛乳の保存期間)2日間では、製剤Eのみが明確な異臭を示した。これはWO07/060247の記載と一致した。しかしながら、反応期間が1ヶ月以上となると、製剤C及びDにおいても異臭が感知された。このことは、ラクターゼ製剤のロングライフミルク等における使用を考えた場合、アリールスルファターゼ活性をWO07/060247に記載の単位で検出限界の8単位としても、十分に異味、異臭をコントロールできないことを示すものである。 In the reaction period of the lactase preparation (that is, the storage period of milk) for 2 days, only preparation E showed a clear off-flavor. This was consistent with the description in WO07 / 060247. However, when the reaction period was 1 month or longer, a bad odor was also detected in preparations C and D. This indicates that when considering the use of a lactase preparation in long-life milk or the like, even if the arylsulfatase activity is the unit described in WO07 / 060247 and the detection limit is 8 units, the taste and odor cannot be sufficiently controlled. It is.
 一方、製剤A及びBでは、反応期間が1ヶ月でも3ヶ月でも異臭は感知されなかった。ラクターゼ製剤のロングライフミルクへの使用を考えた場合、1ヶ月以上の反応期間を想定する必要がある。よって、そのような用途では、ラクターゼ製剤A又はB(すなわち、本発明の方法によるアリールスルファターゼ活性/FCC IV法によるラクターゼ活性が0.02%以下のもの)を使用することが好ましく、ラクターゼ製剤Aの使用がさらに好ましいことが明らかとなった。また、ラクターゼ製剤AやBと同程度のアリールスルファターゼ活性値は、本明細書に記載した蛍光分析法又はそれと同等以上の感度を示す分析法で測定することが必要であることも明らかとなった。 On the other hand, in preparations A and B, no off-flavor was detected even when the reaction period was 1 month or 3 months. When considering the use of lactase preparations in long-life milk, it is necessary to assume a reaction period of one month or longer. Therefore, in such applications, it is preferable to use lactase preparation A or B (that is, those having arylsulfatase activity by the method of the present invention / actase activity by the FCC IV method of 0.02% or less), and lactase preparation A It became clear that the use of was more preferable. Moreover, it became clear that the arylsulfatase activity value comparable to lactase preparations A and B needs to be measured by the fluorescence analysis method described in this specification or an analysis method showing sensitivity equal to or higher than that. .
[実施例5]アリールスルファターゼ産生能が低減された変異株の取得
 二倍体菌株であるクリベロマイセス・ラクティスG14-427株を、YPD培地(1%酵母エキス、1%グルコース、2%ペプトン)10mLに、1白金耳植菌し、この菌懸濁液を30℃に保存して培養し、対数増殖期となったらその培地を遠心分離し、菌体を回収した。回収した菌体を、600nmにおける吸光度が0.5となるように滅菌水に分散させた。この菌懸濁液に、紫外線を、UVランプにて15秒間照射した。遠心分離によって菌体を回収し、YPD培地に混合分散させた。菌体を含むYPD培地から適量を採り、YPD寒天平板培地に塗布した。37℃にて7日間、静置培養を行った。生育してきたコロニーを少量かきとり、これをザイモリエース(生化学バイオビジネス株式会社製)を1mg/mLで含有する溶液1mLに混合した。30℃にて2時間反応させ、細胞壁を破壊した。その後、遠心分離を行い、上清を回収した。
[Example 5] Acquisition of mutant strain with reduced arylsulfatase production ability Cliveromyces lactis G14-427 strain, a diploid strain, was added to 10 mL of YPD medium (1% yeast extract, 1% glucose, 2% peptone). 1 platinum ear was inoculated, and this bacterial suspension was stored at 30 ° C. and cultured. When the logarithmic growth phase was reached, the medium was centrifuged to recover the bacterial cells. The collected cells were dispersed in sterilized water so that the absorbance at 600 nm was 0.5. The bacterial suspension was irradiated with ultraviolet rays for 15 seconds with a UV lamp. The cells were collected by centrifugation and mixed and dispersed in the YPD medium. An appropriate amount was taken from the YPD medium containing the bacterial cells and applied to the YPD agar plate medium. Static culture was performed at 37 ° C. for 7 days. A small amount of the grown colonies were scraped, and this was mixed with 1 mL of a solution containing zymolyce (manufactured by Seikagaku Biobusiness Co., Ltd.) at 1 mg / mL. The reaction was carried out at 30 ° C. for 2 hours to destroy the cell wall. Thereafter, centrifugation was performed and the supernatant was collected.
 上清のラクターゼ活性(FCC IV法)及びアリールスルファターゼ活性(実施例3に記載の蛍光法による)を測定した。アリールスルファターゼ活性/ラクターゼ活性を算出し、その値が小さいもの選択した。 The lactase activity (FCC IV method) and arylsulfatase activity (by the fluorescence method described in Example 3) of the supernatant were measured. The arylsulfatase activity / lactase activity was calculated, and the one with a small value was selected.
 選択された株について、上記の変異処理と選別を繰り返すことにより、二倍体菌株であるクリベロマイセス・ラクティスG14-427株に存在する二つのアリールスルファターゼ遺伝子の中の一つが機能不全となった変異株を取得することができた(SM1182株)。なお、「二つのアリールスルファターゼ遺伝子の中の一つが機能不全となった」との判断は、SM1182株の培養上清のアリールスルファターゼ活性値が、親株であるG14-427株の培養上清のアリールスルファターゼ活性値の約1/2であったことによる。 Mutations in which one of the two arylsulfatase genes present in the diploid strain Kriveromyces lactis G14-427 is dysfunctional by repeating the above mutation treatment and selection for the selected strain. (SM1182 strain). The determination that “one of the two arylsulfatase genes became dysfunctional” is that the arylsulfatase activity value of the SM1182 culture supernatant is the aryl of the culture supernatant of the parent strain G14-427. This is because it was about ½ of the sulfatase activity value.
 さらに、得られた変異株(SM1182株)を親株として変異処理を行い、もう一方のアリールスルファターゼ遺伝子についても機能不全となった、すなわちアリールスルファターゼ活性が0の変異株を取得した(SF-81株)。 Further, the obtained mutant strain (SM1182 strain) was subjected to mutation treatment as a parent strain, and the other arylsulfatase gene also became dysfunctional, that is, a mutant strain having an arylsulfatase activity of 0 was obtained (SF-81 strain) ).
 親株であるクリベロマイセス・ラクティスG14-427株と、上記のようにして得られた変異株2種を、それぞれ、YPD培地(70mL/フラスコ)にて、26℃で4日間振とう培養した。 The parent strain Kriveromyces lactis G14-427 and two mutant strains obtained as described above were each cultured with shaking in a YPD medium (70 mL / flask) at 26 ° C. for 4 days.
 その後、培養液に2mg/mLとなるようザイモリエース(生化学バイオビジネス株式会社製)を加え、30℃にて2時間反応させ、細胞壁を破壊した。遠心分離により上清を回収し、FCC IV法によりラクターゼ活性を、また、実施例3に記載の方法でアリールスルファターゼ活性を測定した。結果を表4に示す。 Thereafter, Zymoly Ace (manufactured by Seikagaku Biobusiness Co., Ltd.) was added to the culture solution so as to be 2 mg / mL, and reacted at 30 ° C. for 2 hours to destroy the cell wall. The supernatant was collected by centrifugation, and lactase activity was measured by the FCC IV method, and arylsulfatase activity was measured by the method described in Example 3. The results are shown in Table 4.
Figure JPOXMLDOC01-appb-T000004
Figure JPOXMLDOC01-appb-T000004
[実施例6]宿主株の取得
 二倍体菌株であるクリベロマイセス・ラクティスG14-427株を、YPD培地10mLに、1白金耳植菌し、30℃にて対数増殖期まで生育させた。培地を遠心分離し、菌体を回収した。回収した菌体を、600nmにおける吸光度が0.5となるように滅菌水に分散させた。この菌懸濁液に、紫外線を、UVランプにて15秒間照射した。遠心分離によって菌体を回収し、YPD培地に混合分散させた。菌体を含むYPD培地から適量を採り、YPD寒天平板培地に塗布した。37℃にて4日間、静置培養を行った。生育してきたコロニーをSD培地(0.67%アミノ酸を含まないイーストナイトロジェンベース、2%グルコース、2%寒天)にレプリカし、生育してこないものを選択した。
[Example 6] Acquisition of host strain The diploid strain Kriveromyces lactis G14-427 was inoculated with 1 platinum ear in 10 mL of YPD medium and grown at 30 ° C until the logarithmic growth phase. The medium was centrifuged and the cells were collected. The collected cells were dispersed in sterilized water so that the absorbance at 600 nm was 0.5. The bacterial suspension was irradiated with ultraviolet rays for 15 seconds with a UV lamp. The cells were collected by centrifugation and mixed and dispersed in the YPD medium. An appropriate amount was taken from the YPD medium containing the bacterial cells and applied to the YPD agar plate medium. Static culture was performed at 37 ° C. for 4 days. The grown colonies were replicated in SD medium (east nitrogen base containing no 0.67% amino acid, 2% glucose, 2% agar), and those that did not grow were selected.
 これらのSD培地では生育しない株を、もとのYPD寒天平板培地より20mg/L L-メチオニンを含むSD培地に塗布し、生育してくるものをL-メチオニン要求株(7-19株)とした。 Those strains that do not grow on the SD medium are applied to an SD medium containing 20 mg / L L-methionine from the original YPD agar plate medium, and those that grow are referred to as L-methionine-requiring strains (7-19 strains). did.
 7-19株を、YPD培地10mLに、1白金耳植菌し、30℃にて対数増殖期まで生育させた。培地を遠心分離し、菌体を回収した。回収した菌体を、600nmにおける吸光度が0.5となるように滅菌水に分散させた。この菌懸濁液に、紫外線を、UVランプにて15秒間照射した。遠心分離によって菌体を回収し、YPD培地に混合分散させた。菌体を含むYPD培地から適量を採り、YPD寒天平板培地に塗布した。37℃にて4日間、静置培養を行った。生育してきたコロニーを20mg/L L-メチオニンを含むSD培地にレプリカし、生育してこないものを選択した。 7-19 strains were inoculated with 1 platinum ear in 10 mL of YPD medium and grown at 30 ° C. until the logarithmic growth phase. The medium was centrifuged and the cells were collected. The collected cells were dispersed in sterilized water so that the absorbance at 600 nm was 0.5. The bacterial suspension was irradiated with ultraviolet rays for 15 seconds with a UV lamp. The cells were collected by centrifugation and mixed and dispersed in the YPD medium. An appropriate amount was taken from the YPD medium containing the bacterial cells and applied to the YPD agar plate medium. Static culture was performed at 37 ° C. for 4 days. The grown colonies were replicated in an SD medium containing 20 mg / L L-methionine, and those that did not grow were selected.
 これらのL-メチオニンを含むSD培地で生育しない株を、もとのYPD寒天平板培地より、20mg/L L-ヒスチジン及び20mg/L L-メチオニンを含むSD培地に塗布し、生育してくるものをL-メチオニン、L-ヒスチジン二重栄養要求株(8-23株)とした。 Those strains that do not grow on the SD medium containing L-methionine are applied to the SD medium containing 20 mg / L L-histidine and 20 mg / L L-methionine from the original YPD agar plate medium and grow. Was L-methionine and L-histidine double auxotrophic strain (8-23 strain).
 取得された栄養要求変異株の生育について、表5に示す。 Table 5 shows the growth of the acquired auxotrophic mutants.
Figure JPOXMLDOC01-appb-T000005
Figure JPOXMLDOC01-appb-T000005
[実施例7]アリールスルファターゼを産生しない遺伝子二重破壊株の取得
(宿主株の取得)
 実施例6で取得したL-ヒスチジン、L-メチオニン二重栄養要求性変異株である8-23株について、それぞれの栄養要求性が、酢酸リチウム法にて導入したHIS4遺伝子及びMET6遺伝子により相補されることを確認した。
[Example 7] Acquisition of gene double disruption strain that does not produce arylsulfatase (acquisition of host strain)
For the 8-23 strain, which is the L-histidine and L-methionine double auxotrophic mutant strain obtained in Example 6, the respective auxotrophy is complemented by the HIS4 gene and the MET6 gene introduced by the lithium acetate method. I was sure that.
(ゲノムDNAの取得)
 二倍体菌株であるクリベロマイセス・ラクティスG14-427株をYPD培地にて培養した。得られた培養液より、GenとるくんTM(酵母用)(タカラバイオ株式会社製)を用いてゲノムDNAを調製した。操作は、GenとるくんTM(酵母用)の説明書の記載に従って行った。
(Acquisition of genomic DNA)
The diploid strain Kriveromyces lactis G14-427 was cultured in YPD medium. Genomic DNA was prepared from the obtained culture solution using Gen Torukun TM (for yeast) (Takara Bio Inc.). The operation was performed according to the description of Gen Torukun TM (for yeast).
(アリールスルファターゼ遺伝子破壊ベクターの構築)
 アリールスルファターゼ遺伝子のオープン・リーディング・フレームが含まれた断片が取得されるように、プライマーSuC-F及びSuC-Rを設計した。これらを含む、使用したプライマーの配列は、表6に示すとおりであった。
(Construction of arylsulfatase gene disruption vector)
Primers SuC-F and SuC-R were designed so that a fragment containing the open reading frame of the arylsulfatase gene was obtained. The primer sequences used, including these, were as shown in Table 6.
Figure JPOXMLDOC01-appb-T000006
Figure JPOXMLDOC01-appb-T000006
 先に調製したゲノムDNAを鋳型とし、上記プライマーを用いて次に示す条件によりPCRを行い、DNA断片を取得した。なお、ポリメラーゼとして、Takara Ex Taq(登録商標;タカラバイオ株式会社製)を用い、操作はその添付文書に従って行った。 Using the genomic DNA prepared previously as a template, PCR was performed using the above primers under the following conditions to obtain a DNA fragment. In addition, Takara Ex Taq (registered trademark; manufactured by Takara Bio Inc.) was used as the polymerase, and the operation was performed according to the attached document.
(PCR条件)
Stage1(1サイクル)  94℃  3分
Stage2(30サイクル) 94℃  1分
               54℃  1分
               72℃  3分
Stage3(1サイクル)  72℃ 10分
               4℃に保持
(PCR conditions)
Stage 1 (1 cycle) 94 ° C. 3 minutes Stage 2 (30 cycles) 94 ° C. 1 minute 54 ° C. 1 minute 72 ° C. 3 minutes Stage 3 (1 cycle) 72 ° C. 10 minutes Hold at 4 ° C.
 得られた断片をMagExtractorTM-PCR&Gel Clean up-(東洋紡株式会社製)にて精製し、その後pGEM(登録商標)-Tベクター(Promega社製)とライゲーション反応を行わせた。ライゲーション反応には、DNA Ligation Kit<Mighty Mix>(タカラバイオ株式会社製)を用いた。使用法はそれぞれの添付文書に従った。その後、ハナハン法(Hanahan,D.,J.Mol.Biol.,166,557(1983))にて調製したE.ColiDH5α株のコンピテントセルを形質転換し、得られた形質転換体の培養液より、MagExtractorTM-Plasmid-(東洋紡株式会社製)を用いてプラスミドを抽出した。使用法は添付文書に従った。その結果、目的の断片がサブクローニングされたプラスミドpGSuCが得られた。 The obtained fragment was purified by MagExtractor -PCR & Gel Clean up- (manufactured by Toyobo Co., Ltd.), and then ligated with a pGEM (registered trademark) -T vector (manufactured by Promega). For the ligation reaction, DNA Ligation Kit <Mighty Mix> (manufactured by Takara Bio Inc.) was used. Usage was in accordance with each package insert. Thereafter, E. coli prepared by the Hanahan method (Hanahan, D., J. Mol. Biol., 166, 557 (1983)). A competent cell of ColiDH5α strain was transformed, and a plasmid was extracted from the obtained transformant culture solution using MagExtractor -Plasmid- (manufactured by Toyobo Co., Ltd.). Usage followed the package insert. As a result, a plasmid pGSuC in which the target fragment was subcloned was obtained.
 さらに、プライマーBGLHIS4-F及びHIS4-Rを用い、ゲノムDNAを鋳型としてPCRを行い、HIS4遺伝子を含む断片を取得した。PCR反応については、前述の方法に従った。図3に示すように、得られたHIS4遺伝子を含む断片をBgl II及びEcoRIにて処理し、pGSuCのBgl II-EcoRIサイトに挿入した。このようにして構築したプラスミドを、pdSuC1と名付けた。構築時の各種方法は、前述の方法と同様であった。 Furthermore, PCR was performed using primers BGLHIS4-F and HIS4-R using genomic DNA as a template to obtain a fragment containing the HIS4 gene. For the PCR reaction, the method described above was followed. As shown in FIG. 3, the obtained fragment containing the HIS4 gene was treated with Bgl II and EcoRI and inserted into the Bgl II-EcoRI site of pGSuC. The plasmid constructed in this way was named pdSuC1. Various methods at the time of construction were the same as those described above.
 また、MET6遺伝子をマーカーとしたアリールスルファターゼ遺伝子破壊ベクターを構築するために、5´側にアリールスルファターゼ遺伝子の相同配列を40塩基付加したプライマーSuCd-M6F及びSuCd-M6Rを設計した。アリールスルファターゼ遺伝子の相同配列は、オープン・リーディング・フレーム上に2ヶ所存在する制限酵素ClaI部位付近とした。図4に示すように、これらのプライマーを用い、ゲノムDNAを鋳型として、MET6遺伝子の両端にアリールスルファターゼの相同配列を持つ断片を取得した。得られた断片をpGEM(登録商標)-Tベクター(Promega社製)にサブクローニングし、pdSuCM6を得た。構築時の各種方法は、前述の方法と同様であった。 In addition, in order to construct an arylsulfatase gene disruption vector using the MET6 gene as a marker, primers SuCd-M6F and SuCd-M6R were designed by adding 40 bases of the homologous sequence of the arylsulfatase gene to the 5 ′ side. The homologous sequence of the arylsulfatase gene was in the vicinity of the restriction enzyme ClaI site present in two places on the open reading frame. As shown in FIG. 4, using these primers, a fragment having an arylsulfatase homologous sequence at both ends of the MET6 gene was obtained using genomic DNA as a template. The obtained fragment was subcloned into pGEM (registered trademark) -T vector (Promega) to obtain pdSuCM6. Various methods at the time of construction were the same as those described above.
(アリールスルファターゼ遺伝子破壊ベクターを用いたL-メチオニン、L-ヒスチジン二重栄養要求性8-23株の形質転換)
 図5に、形質転換体構築の模式図を示す。プラスミドpdSuC1を、NcoI及びAatIIで処理して直鎖状にし、それを用いて8-23株を酢酸リチウム法により形質転換し、20μg/mlのメチオニンを添加したSD培地で生育する形質転換体SuCD株を取得した。
(Transformation of L-methionine and L-histidine double auxotrophic strain 8-23 using an arylsulfatase gene disruption vector)
FIG. 5 shows a schematic diagram of the construction of the transformant. The plasmid pdSuC1 is linearized by treatment with NcoI and AatII, and the strain 8-23 is transformed by the lithium acetate method using this, and the transformant SuCD grows in SD medium supplemented with 20 μg / ml methionine. Acquired shares.
 次に、プラスミドpdSuCM6をClaIで処理して直鎖状にし、それを用いてSuCD株を酢酸リチウム法により形質転換し、SD培地で生育する形質転換体SuCDD5-2株を得た。 Next, the plasmid pdSuCM6 was treated with ClaI to form a linear form, and the SuCD strain was transformed by the lithium acetate method using it to obtain a transformant SuCDD5-2 strain that grew on the SD medium.
(親株及び形質転換株のDNAのサザン・ブロッティング)
 得られた形質転換体を、それぞれYPD培地にて培養し、その培養液よりGenとるくんTM(酵母用)(タカラバイオ株式会社製)を用いてゲノムDNAを調製した。得られたゲノムDNAをBamHIで消化後、サザン解析を行った。プローブはアリールスルファターゼ遺伝子のAatII-EcoRI断片を用い、核酸の標識と検出には、AlkPhos Direct Labelling and Detection System with CDP-Star(GEヘルスケア バイオサイエンス株式会社製)を用い、使用法は添付文書に従った。
(Southern blotting of parental and transformed DNA)
Each of the obtained transformants was cultured in a YPD medium, and genomic DNA was prepared from the culture solution using Gentorikun TM (for yeast) (manufactured by Takara Bio Inc.). The obtained genomic DNA was digested with BamHI and then subjected to Southern analysis. The probe used was an AatII-EcoRI fragment of an arylsulfatase gene, and for labeling and detection of nucleic acids, AlkPhos Direct Labeling and Detection System with CDP-Star (manufactured by GE Healthcare Biosciences) was used. I followed.
 サザン・ブロッティングの結果を図6に示す。レーン1が親株G14-427株、レーン2が形質転換体SuCDD5-2株、レーン3が形質転換体SuCD株である。レーン3には、アリールスルファターゼ遺伝子とHIS4遺伝子を含む断片のバンド(12.1kb)とともに、レーン1と同じ位置(7.8kb)にもバンドが検出され、アリールスルファターゼ遺伝子の一方のみが破壊されていることが確認された。一方、レーン2では、7.8kbのバンドが5.3kbにシフトしており、アリールスルファターゼ遺伝子二重破壊株であることが確認された。 The result of Southern blotting is shown in FIG. Lane 1 is the parent strain G14-427, Lane 2 is the transformant SuCDD5-2 strain, and Lane 3 is the transformant SuCD strain. In lane 3, a band (12.1 kb) of the fragment containing the arylsulfatase gene and the HIS4 gene was detected at the same position (7.8 kb) as in lane 1, and only one of the arylsulfatase genes was destroyed. It was confirmed that On the other hand, in lane 2, the 7.8 kb band was shifted to 5.3 kb, confirming that it was an arylsulfatase gene double disruption strain.
(アリールスルファターゼ遺伝子二重破壊株のアリールスルファターゼ活性の検出)
 親株である二倍体菌株のクリベロマイセス・ラクティスG14-427株及び上記のようにして構築したSuCDD5-2株を、それぞれYPD培地に接種し、30℃、210rpmにて72時間、振とう培養した。培養液に2mg/mlとなるようにザイモリエース(生化学バイオビジネス株式会社製)を加え、30℃に2時間反応させ、細胞壁を破壊した。遠心分離により上清を回収し、FCC IV法によってラクターゼ活性を、そして実施例3に記載の方法でアリールスルファターゼ活性を測定した。結果を表7に示す。
(Detection of arylsulfatase activity in an arylsulfatase gene double disruption strain)
The parent diploid strain Kriveromyces lactis G14-427 and the SuCDD5-2 strain constructed as described above were inoculated in a YPD medium and cultured with shaking at 30 ° C. and 210 rpm for 72 hours. Zymoly ace (manufactured by Seikagaku Biobusiness Co., Ltd.) was added to the culture solution so as to be 2 mg / ml, and reacted at 30 ° C. for 2 hours to destroy the cell wall. The supernatant was collected by centrifugation, and lactase activity was measured by the FCC IV method, and arylsulfatase activity was measured by the method described in Example 3. The results are shown in Table 7.
 SuCDD5-2株の培養液には、ラクターゼは含まれているが、アリールスルファターゼは含まれていないか、含まれていたとしてもその活性が蛍光法による測定において検出されないような微量であることが明らかとなった。即ち、SuCDD5-2株は、ラクターゼの生産性は維持しているが、アリールスルファターゼの生産性は0であるか又は殆どないことが確認された。 The culture medium of the SuCDD5-2 strain contains lactase, but does not contain arylsulfatase, or even if it is contained, the amount of the activity may not be detected by fluorescence measurement. It became clear. That is, it was confirmed that the SuCDD5-2 strain maintained lactase productivity but had no or almost no arylsulfatase productivity.
Figure JPOXMLDOC01-appb-T000007
Figure JPOXMLDOC01-appb-T000007
[実施例8] 酵素製剤の調製
 実施例5で得たSF-81株を、7%コーンスチーブリカー、2%乳糖を含有するラクターゼ生産用培地に接種し、30℃、210rpmにて96時間、振とう培養後、遠心分離により菌体を回収した。菌体に滅菌精製水を加え、ガラスビーズと超音波により、回収菌体の細胞壁を破壊し、遠心分離により上清を回収した。上清を硫安分画し、限外ろ過膜で濃縮することにより、ラクターゼ活性が5000NLU/gのラクターゼ製剤を得た。このラクターゼ製剤のアリールスルファターゼ活性は、本発明の測定法(蛍光法)によると、1U/g以下であった。
[Example 8] Preparation of enzyme preparation The strain SF-81 obtained in Example 5 was inoculated into a lactase production medium containing 7% corn steep liquor and 2% lactose, and the mixture was incubated at 30 ° C and 210 rpm for 96 hours. After shaking culture, the cells were collected by centrifugation. Sterile purified water was added to the cells, the cell walls of the collected cells were broken with glass beads and ultrasonic waves, and the supernatant was collected by centrifugation. The supernatant was fractionated with ammonium sulfate and concentrated with an ultrafiltration membrane to obtain a lactase preparation having a lactase activity of 5000 NLU / g. The arylsulfatase activity of this lactase preparation was 1 U / g or less according to the measurement method (fluorescence method) of the present invention.
[実施例9]風味官能試験(その2)
(様々なアリールスルファターゼ夾雑率のラクターゼ製剤の調製)
 実施例8に記載の方法でSF-81株から製造したラクターゼ製剤そのもの、及びこれにGODO-YNL2を適宜混合して、実施例3に示した蛍光法で測定したアリールスルファターゼ活性が1乃至20U/gのラクターゼ製剤5種を調製した。また、各ラクターゼ製剤のラクターゼ活性を、FCC IV法によって測定した。
[Example 9] Sensory sensory test (2)
(Preparation of lactase preparations with various arylsulfatase contamination rates)
A lactase preparation itself produced from the SF-81 strain by the method described in Example 8 and an appropriate mixture of GODO-YNL2 and an arylsulfatase activity measured by the fluorescence method described in Example 3 are 1 to 20 U / 5 lactase preparations were prepared. Moreover, the lactase activity of each lactase preparation was measured by FCC IV method.
(風味官能試験)
 実施例4同様、市販牛乳に、ラクターゼが20000NLU/L-牛乳となるように、上記ラクターゼ製剤5種の各々を加え、30℃に保存した。保存1ヶ月後に、ラクターゼ製剤を添加していない牛乳とラクターゼ製剤を添加した牛乳を比較する風味官能試験を、実施例4と同様の方法で行った。結果を表8に示す。
(Flavor sensory test)
As in Example 4, each of the above 5 lactase preparations was added to commercially available milk so that the lactase was 20000 NLU / L-milk and stored at 30 ° C. After 1 month of storage, a flavor sensory test was performed in the same manner as in Example 4 to compare milk without a lactase preparation and milk with a lactase preparation. The results are shown in Table 8.
Figure JPOXMLDOC01-appb-T000008
Figure JPOXMLDOC01-appb-T000008
 表8に示された結果より、本発明に係る方法で測定したアリールスルファターゼ活性は、5U/g以下であることが好ましいことがわかった。また、FCC IV法によるラクターゼ活性(単位:NLU/g)を基準として、本発明に係る方法で測定したアリールスルファターゼ活性(単位:U/g)の割合は、0.1%以下であることが好ましいことも明らかとなった。 From the results shown in Table 8, it was found that the arylsulfatase activity measured by the method according to the present invention is preferably 5 U / g or less. The ratio of arylsulfatase activity (unit: U / g) measured by the method according to the present invention based on lactase activity (unit: NLU / g) by FCC IV method may be 0.1% or less. It became clear that it was preferable.

Claims (7)

  1. ラクターゼ遺伝子を有し且つアリールスルファターゼ蛋白の発現が制限されている酵母の二倍体菌株又は酵母のラクターゼ遺伝子が導入され且つアリールスルファターゼ蛋白の発現が制限されている遺伝子組換え微生物の培養液を原料として製造されたラクターゼ製剤であって、FCC IV法によるラクターゼ活性(単位:NLU/g)を基準として、下記の方法で測定し、計算したアリールスルファターゼ活性(単位:U/g)が0.1%以下であることを特徴とするラクターゼ製剤:
    (アリールスルファターゼ活性の測定方法)
    (1)アリールスルファターゼの存在が予測される検体を、0.5N塩化カリウムを含む100mMリン酸カリウム緩衝液(pH6.5)で適宜希釈し、サンプルとする。 
    (2)4-メチルウンベリフェロンスルフェイトカリウムを2mM濃度で含有する水溶液を調製する。
    (3)サンプルと4-メチルウンベリフェロンスルフェイトカリウム水溶液とを、1:1(容量基準)で混合し、37℃にて3時間反応させる。
    (4)反応液に、反応液と同量(容量基準)の0.1N水酸化ナトリウム水溶液を添加し、反応を停止させ、測定用サンプルとする。
    (5)励起波長360nm、蛍光波長450nmにて、蛍光強度を測定する。
    (6)4-メチルウンベリフェロンを、0.5N塩化カリウムを含む100mMリン酸カリウム緩衝液(pH6.5)に溶解させ、適切な濃度の溶液とし、(4)と同様に0.1N水酸化ナトリウム水溶液を添加し、(5)と同様の条件で蛍光強度を測定する。
    (7)(6)より、検量線を作成する。
    (8)(5)で測定された蛍光強度と(7)で作成された検量線から、測定用サンプルの4-メチルウンベリフェロン濃度を算出し、それを3で割り、反応時間が1時間であった場合の4-メチルウンベリフェロン濃度を求める。さらに、反応液の容量から、1時間の反応中に生じた4-メチルウンベリフェロン量を算出する。
    (9)こうして算出された4-メチルウンベリフェロン量は、(1)で調製したサンプルに含有されていた検体量に基づくものであるので、検体1g当たりの4-メチルウンベリフェロン量に換算する。
    (10)基質と酵素との反応時間1時間あたりの4-メチルウンベリフェロン生成量が1nmoleであった場合を1ユニット(U)とし、単位は、検体、即ち酵素製剤1g当たりのユニット量、即ち「ユニット(U)/g」で表す。
    A yeast diploid strain that has a lactase gene and expression of arylsulfatase protein is restricted, or a culture solution of a genetically modified microorganism into which yeast lactase gene is introduced and expression of arylsulfatase protein is restricted A lactase preparation produced as above, wherein the calculated arylsulfatase activity (unit: U / g) measured by the following method based on the lactase activity (unit: NLU / g) by the FCC IV method was 0.1 % Lactase preparation characterized by:
    (Measurement method of arylsulfatase activity)
    (1) A specimen in which the presence of arylsulfatase is predicted is appropriately diluted with a 100 mM potassium phosphate buffer (pH 6.5) containing 0.5 N potassium chloride to prepare a sample.
    (2) An aqueous solution containing 2-methylumbelliferone sulfate potassium at a concentration of 2 mM is prepared.
    (3) The sample and a 4-methylumbelliferone sulfate aqueous solution are mixed at 1: 1 (volume basis) and reacted at 37 ° C. for 3 hours.
    (4) To the reaction solution, add the same amount (volume basis) of 0.1N sodium hydroxide aqueous solution as the reaction solution to stop the reaction and prepare a measurement sample.
    (5) The fluorescence intensity is measured at an excitation wavelength of 360 nm and a fluorescence wavelength of 450 nm.
    (6) 4-Methylumbelliferone is dissolved in a 100 mM potassium phosphate buffer (pH 6.5) containing 0.5N potassium chloride to obtain a solution with an appropriate concentration. An aqueous sodium oxide solution is added, and the fluorescence intensity is measured under the same conditions as in (5).
    (7) A calibration curve is created from (6).
    (8) From the fluorescence intensity measured in (5) and the calibration curve created in (7), the 4-methylumbelliferone concentration of the measurement sample is calculated, divided by 3, and the reaction time is 1 hour. If so, determine the 4-methylumbelliferone concentration. Further, the amount of 4-methylumbelliferone generated during the reaction for 1 hour is calculated from the volume of the reaction solution.
    (9) Since the amount of 4-methylumbelliferone calculated in this way is based on the amount of sample contained in the sample prepared in (1), it is converted to the amount of 4-methylumbelliferone per gram of sample. To do.
    (10) The case where the amount of 4-methylumbelliferone produced per 1 hour of the reaction time between the substrate and the enzyme is 1 nmole is defined as 1 unit (U), and the unit is the unit amount per 1 g of the specimen, that is, the enzyme preparation, That is, it is represented by “unit (U) / g”.
  2. 酵母がクリベロマイセス・ラクティス又はクリベロマイセス・マリキシアヌスである、請求項1に記載のラクターゼ製剤。 The lactase preparation according to claim 1, wherein the yeast is Krivellomyces lactis or Krivellomyces marixianus.
  3. FCC IV法によるラクターゼ活性(単位:NLU/g)を基準としたアリールスルファターゼ活性(単位:U/g)が0.02%以下である、請求項1又は2に記載のラクターゼ製剤。 The lactase preparation according to claim 1 or 2, wherein an arylsulfatase activity (unit: U / g) based on lactase activity (unit: NLU / g) by FCC IV method is 0.02% or less.
  4. ラクターゼ遺伝子を有し且つアリールスルファターゼ蛋白の発現が制限されている酵母の二倍体菌株が、ラクターゼ遺伝子を有する酵母の二倍体菌株の変異処理によって取得された変異株である、請求項1乃至3のいずれか一項に記載のラクターゼ製剤。 The diploid strain of yeast having a lactase gene and restricted expression of arylsulfatase protein is a mutant obtained by mutation treatment of a yeast diploid strain having a lactase gene. The lactase preparation according to any one of 3 above.
  5. ラクターゼ遺伝子を有し且つアリールスルファターゼ蛋白の発現が制限されている酵母の二倍体菌株が、ラクターゼ遺伝子を有する酵母の二倍体菌株の、アリールスルファターゼ遺伝子又はアリールスルファターゼ蛋白発現調節遺伝子の欠失操作によって得られた変異株である、請求項1乃至3のいずれか一項に記載のラクターゼ製剤。 Deletion of an aryl sulfatase gene or an aryl sulfatase protein expression regulatory gene of a yeast diploid strain having a lactase gene and restricted expression of an aryl sulfatase protein. The lactase preparation according to any one of claims 1 to 3, which is a mutant obtained by the method.
  6. ラクターゼ遺伝子を有し且つアリールスルファターゼ蛋白の発現が制限されている酵母の二倍体菌株又は酵母のラクターゼ遺伝子が導入され且つアリールスルファターゼ蛋白の発現が制限されている遺伝子組換え微生物を培養し、細胞壁を破壊し又は破壊せずに培養液を回収し、ラクターゼ製剤を調製することを特徴とするラクターゼ製剤の製造方法。 Culturing a diploid strain of yeast having a lactase gene and restricted expression of arylsulfatase protein or a genetically modified microorganism introduced with a yeast lactase gene and restricted in expression of arylsulfatase protein. A method for producing a lactase preparation, comprising: recovering a culture solution without destroying or destroying the preparation to prepare a lactase preparation.
  7. 請求項1乃至5のいずれか一項に記載されたラクターゼ製剤を用いて製造されたことを特徴とする乳製品。 A dairy product produced using the lactase preparation according to any one of claims 1 to 5.
PCT/JP2009/066231 2009-09-17 2009-09-17 Lactase preparation WO2011033633A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/JP2009/066231 WO2011033633A1 (en) 2009-09-17 2009-09-17 Lactase preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2009/066231 WO2011033633A1 (en) 2009-09-17 2009-09-17 Lactase preparation

Publications (1)

Publication Number Publication Date
WO2011033633A1 true WO2011033633A1 (en) 2011-03-24

Family

ID=43758259

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/066231 WO2011033633A1 (en) 2009-09-17 2009-09-17 Lactase preparation

Country Status (1)

Country Link
WO (1) WO2011033633A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012124668A1 (en) * 2011-03-14 2012-09-20 合同酒精株式会社 Method for assaying arylsulfatase activity
CN104155260A (en) * 2014-08-28 2014-11-19 南通大学 Method for directly measuring major sulfate radical by using ultraviolet spectrophotometry
WO2014185364A1 (en) * 2013-05-13 2014-11-20 合同酒精株式会社 Method for producing lactase-containing composition
WO2017073723A1 (en) * 2015-10-29 2017-05-04 合同酒精株式会社 Milk or milk product
WO2018229259A1 (en) * 2017-06-16 2018-12-20 Weissbiotech Gmbh Enzyme product with beta-galactosidase

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002253212A (en) * 2001-03-02 2002-09-10 Yamaguchi Technology Licensing Organization Ltd Auxotrophic mutant of useful yeast and method for breeding the variant
JP2009517061A (en) * 2005-11-28 2009-04-30 ディーエスエム アイピー アセッツ ビー.ブイ. Enzyme preparation that produces a clean taste

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002253212A (en) * 2001-03-02 2002-09-10 Yamaguchi Technology Licensing Organization Ltd Auxotrophic mutant of useful yeast and method for breeding the variant
JP2009517061A (en) * 2005-11-28 2009-04-30 ディーエスエム アイピー アセッツ ビー.ブイ. Enzyme preparation that produces a clean taste

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012124668A1 (en) * 2011-03-14 2012-09-20 合同酒精株式会社 Method for assaying arylsulfatase activity
WO2014185364A1 (en) * 2013-05-13 2014-11-20 合同酒精株式会社 Method for producing lactase-containing composition
JPWO2014185364A1 (en) * 2013-05-13 2017-02-23 合同酒精株式会社 Method for producing lactase-containing composition
US9848614B2 (en) 2013-05-13 2017-12-26 Godo Shusei Co., Ltd. Method for producing lactase-containing composition
CN104155260A (en) * 2014-08-28 2014-11-19 南通大学 Method for directly measuring major sulfate radical by using ultraviolet spectrophotometry
WO2017073723A1 (en) * 2015-10-29 2017-05-04 合同酒精株式会社 Milk or milk product
JP2019004701A (en) * 2015-10-29 2019-01-17 合同酒精株式会社 Milk or dairy product
WO2018229259A1 (en) * 2017-06-16 2018-12-20 Weissbiotech Gmbh Enzyme product with beta-galactosidase

Similar Documents

Publication Publication Date Title
JP6013321B2 (en) Method for measuring the activity of arylsulfatase
Chen et al. Production, purification, and characterization of a potential thermostable galactosidase for milk lactose hydrolysis from Bacillus stearothermophilus
Choi et al. Characterization and heterologous gene expression of a novel esterase from Lactobacillus casei CL96
KR102533803B1 (en) Bacillus host cells producing β-galactosidase and lactase in the absence of p-nitrobenzylesterase activator
WO2011033633A1 (en) Lactase preparation
CN1056648C (en) Hyperthermostable beta-galactosidase gene
CN103937830B (en) A kind of recombinant bacterium of efficient secretory expression Nattokinase
KR100452447B1 (en) Ultra High Temperature Stability Protease Gene
JPH07123977A (en) Lactic bacteria and fermented dairy product
Stressler et al. Homologous expression and biochemical characterization of the arylsulfatase from Kluyveromyces lactis and its relevance in milk processing
JP3327469B2 (en) Methods for biological inactivation of nucleic acids
JP2018525988A (en) Bacillus subtilis strain with high production of thrombolytic enzymes
US7371550B2 (en) Cholesterol oxidase stable in the presence of surfactant
Moschopoulou Microbial milk coagulants
JP7316758B2 (en) Lactase preparations that can reduce the risk of off-flavours
EP0402450A1 (en) Production of fermented food products.
EP1535999B1 (en) Milk-coagulating enzyme originating in bacterium and process for producing cheese using the same
Azar et al. Expression and response surface optimization of the recovery and purification of recombinant D-galactose dehydrogenase from Pseudomonas fluorescens
JP5926818B2 (en) Cell killing method using polyethylene glycol nonionic surfactant
JP4415247B2 (en) Novel glycerol kinase, gene and method for producing glycerol kinase using the gene
US20110306139A1 (en) Mutant Cells Suitable For Recombinant Polypeptide Production
JP3516318B2 (en) Novel endopeptidase
RU2388825C1 (en) FERMENT CARBOXYPEPTIDASE KPSB, STRAIN Streptomyces bikiniensis-PRODUCER OF CARBOXYPEPTIDASE KPSB; FRAGMENT OF DNA SB27-995, WHICH CODES SYNTHESIS OF THIS FERMENT MATURE FORM, AND METHOD FOR MICROBIOLOGICAL SYNTHESIS OF CARBOXYPEPTIDASE KPSB
JPS5955186A (en) Preparation of heat-resistant enzyme
CA3066575A1 (en) Enzyme product with beta-galactosidase

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09849492

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09849492

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP